Levi & Korsinsky notifies investors that it has commenced an investigation into Qualys, Inc. (NASDAQ: QLYS) concerning potential violations of the federal securities laws.
Qualys is the subject of a report published by the Investors Business Daily on February 5, 2024. According to the report, a Morgan Stanley anlyst report stated, "Microsoft recently announced plans to end its partnership with Qualys as the default provider of vulnerability scanning within Microsoft Defender, effective May 1. With Microsoft being one of Qualys' largest customers and partners, we see top-line risks as potentially material." Following this news, shares of Qualys dropped on the same day. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
If you suffered a loss on your Qualys securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Coinbase Global, Inc. (NASDAQ: COIN) concerning potential violations of the federal securities laws.
The Financial Conduct Authority ("FCA"), a U.K. financial regulator, issued a press release on July 25, 2024, announcing that it had fined Coinbase's U.K. unit CB Payments Limited ("CBPL") approximately $4.5 million "for repeatedly breaching a requirement that prevented the firm from offering services to high-risk customers." The FCA noted that "[t]he breaches were the result of CBPL's lack of due skill, care and diligence in the design, testing, implementation and monitoring of the controls put in place" to prevent such violations. Following this news, Coinbase's stock price dropped over 5% the same day.
If you suffered a loss on your Coinbase securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into LPL Financial Holdings Inc. (NASDAQ: LPLA) concerning potential violations of the federal securities laws.
On July 5, 2024, a federal judge granted Ameriprise Financial, Inc.’s (“Ameriprise’s”) request for a temporary restraining order against LPL after two former Ameriprise brokers joined LPL and allegedly used confidential client information to improperly solicit their former clients to switch firms. Following this news, the price of LPL Financial shares declined on July 5, 2024 to close at $272.52 on July 8, 2024.
If you suffered a loss on your LPL Financial securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into MaxLinear, Inc. (NASDAQ: MXL) concerning potential violations of the federal securities laws.
On July 24, 2024, after the market closed, MaxLinear announced earnings results for its second quarter of 2024 and that net revenue for the quarter was just $92 million, down 50% year-over-year. The company attributed the decline at least in part to prolonged burn-off of excess customer inventory leading to weakened demand. The news caused a precipitous decline in the price of MaxLinear stock. The price of the company’s stock closed at $22.29 per share on July 24, 2024. Prior to the market open, MaxLinear stock declined 26% on July 25, 2024.
If you suffered a loss on your MaxLinear securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into General Motors Company (NYSE: GM) concerning potential violations of the federal securities laws.
GM filed a petition in 2022, with the National Highway Traffic Safety Administration seeking permission to deploy up to 2,500 self-driving Origin vehicles annually without human controls such as a steering wheel, brake pedals or mirrors. Then, on July 23, 2024, GM announced that it was indefinitely delaying its planned Origin vehicle, stating that it would instead use a conventional next-generation Bolt electric vehicle as the platform for its planned Cruise robotaxi. Following this news, GM's stock price dropped over 6% on July 23, 2024.
If you suffered a loss on your General Motors securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Tesla, Inc. (NASDAQ: TSLA) concerning potential violations of the federal securities laws.
On July 23, 2024, after the market closed, Tesla announced its Q2 2024 results, reporting lower earnings-per-share ("EPS") and operating income than anticipated. Specifically, EPS came in at $0.52 vs. $0.62 consensus and $0.91 a year ago and, while operating margin was reported at 6.3% of sales to improve from last quarter's mark of 5.5%, this figure landed below last year's mark of 9.6%. In addition, although Tesla promised a "fleet" of robotaxis and was optimistic regarding the Company's autonomous driving system, market analysts reported that investors focused more on the Company's Q2 EPS miss, disappointing operating margins and free cash flow lines, and slower 2024 growth forecast. Following this news, Tesla's stock price dropped over 12% on July 24, 2024.
If you suffered a loss on your Tesla securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Allarity Therapeutics, Inc. (NASDAQ: ALLR) concerning potential violations of the federal securities laws.
Allarity disclosed on July 22, 2024, that it received a Wells Notice from the SEC concerning “the Company’s disclosures regarding meetings with the United States Food and Drug Administration (the “FDA”) regarding the Company’s NDA for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021.” On this news, the price of the Company’s stock dropped.
If you suffered a loss on your Allarity securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) concerning potential violations of the federal securities laws.
4D Molecular Therapeutics released the interim results of its Phase 2 PRISM study on Intravitreal 4D-150 on July 17, 2024. Despite the Company billing the results as positive, the stock fell by more than 35.8% in afternoon trading on the same day. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
If you suffered a loss on your 4D Molecular Therapeutics securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Medpace Holdings, Inc. (NASDAQ: MEDP) concerning potential violations of the federal securities laws.
On July 22, 2024, after market hours, MedPace announced mixed financial results for the second quarter of 2024 and then slashed its revenue guidance for the third quarter and remainder of the year. Analysts referred to the company’s bookings miss as “significantly worse” than imagined and revised their outlooks accordingly. In response to MedPace’s announcements, the company’s stock price opened approximately 17% lower than the prior day’s closing price.
If you suffered a loss on your Medpace securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired United Parcel Service, Inc. (NYSE: UPS) securities.
If you suffered a loss on your UPS investment and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
THE LAWSUIT: Jan 30 2024 - Jul 22 2024
CASE DETAILS: According to the complaint, defendants provided investors with material information concerning UPS’ expected revenue and adjusted operating margin for the fiscal year 2024. Defendants’ statements included, among other things, confidence in the Company’s volume growth, price discipline, cost execution, and its overall ability to handle volume variabilities. Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of UPS’ growth; notably, that it was not truly equipped to handle a surge in volume in lower-profit services without seeing a significant decline in their operating margins. Such statements absent these material facts caused shareholders to purchase UPS’ securities at artificially inflated prices. The truth emerged on July 23, 2024 when UPS announced its financial results for the second quarter of fiscal 2024, provided lower-than-expected guidance for the third quarter, and reduced its margin guidance for the full fiscal year 2024. The Company attributed its results and lowered guidance on the shift in “U.S. volume mix both in terms of product and customer segmentation . . . toward value products.” Investors and analysts reacted immediately to UPS’ revelation. The price of UPS’ common stock declined dramatically. From a closing market price of $145.18 per share on July 22, 2024, UPS’ stock price fell to $127.68 per share on July 23, 2024, a decline of $17.50 per share, or about 12.05% in the span of just a single day.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into ResMed Inc. (NYSE: RMD) concerning potential violations of the federal securities laws.
On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023. Analysts lowered their ratings in response to ResMed’s report, citing concerns over market share and gross margins. Following ResMed’s announcements, on August 4, 2023, ResMed’s stock price fell from $219.95 per share to $179.25 per share, a decline of more than $40 per share.
If you suffered a loss on your ResMed securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Sabre Corporation (NASDAQ: SABR) concerning potential violations of the federal securities laws.
On February 15, 2024, Sabre announced Q4 FY2023 financial results that missed analysts’ expectations. Additionally, the Company updated its revenue guidance and adjusted EBITDA outlook for Q1 and full year 2024 that was below analysts’ estimates. Analysts commenting on the lowered guidance noted the Company’s declining revenue over the last five years and its “large exposure” to the uncertainty of long-haul corporate travel in the industry. Following this news, Sabre’s stock price fell by $0.99 per share, or approximately 22% to close at $3.42 per share.
If you suffered a loss on your Sabre securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Cryoport, Inc. (NASDAQ: CYRX) concerning potential violations of the federal securities laws.
On May 7, 2024, Cryoport announced “disappointing” first quarter earnings for fiscal 2024. Jerrell Shelton, CEO of Cryoport, attributed the weak earnings to a “difficult environment globally” and “softer than anticipated” revenue growth in the company’s Life Sciences Services segment. On this news, Cryoport’s stock price fell $3.20 per share or nearly 20% in the span of just a day.
If you suffered a loss on your Cryoport securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into CVRx, Inc. (NASDAQ: CVRX) concerning potential violations of the federal securities laws.
On July 10, 2024, the Centers for Medicare and Medicaid Services ("CMS") issued proposed payment rates for hospital outpatient and Ambulatory Surgical Center ("ASC") services. That same day, Piper Sandler released a note stating that under the proposed CMS rules, reimbursement for CVRx's Barostim heart failure device has been reduced by 38.1% for ASC services and by 32.9% for Hospital Outpatient Department services. Following this news, CVRx's stock price dropped over 38% the same day.
If you suffered a loss on your CVRx, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Lifecore Biomedical, Inc. (NASDAQ: LFCR) concerning potential violations of the federal securities laws.
Lifecore announced on March 20, 2024, that its Board of Directors had concluded its review of strategic alternatives, in which it "unanimously concluded that the best way to maximize value for stockholders at this time is to continue executing on the Company's standalone strategic plan." The Company also announced a leadership transition by naming a new CEO. Following this news, shares of Lifecore dropped over 35% in morning trading on the same day.
If you suffered a loss on your Lifecore securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into GE Vernova Inc. (NYSE: GEV) concerning potential violations of the federal securities laws.
GE Vernova became the subject of a Wall Street Journal article on July 17, 2024. According to the Journal, “GE Vernova’s shares plunged 9.3% on Wednesday, two days after news emerged that an under-construction offshore wind project, Vineyard Wind 1, that uses its turbines, experienced “blade damage,” causing debris to wash up on the shores of Nantucket.” Following this news, investors suffered damages.
If you suffered a loss on your GE Vernova securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into CenterPoint Energy, Inc. (NYSE: CNP) concerning potential violations of the federal securities laws.
Hurricane Beryl made landfall in Texas as a Category 1 storm on July 8, 2024. The impact of the storm left roughly 2.2 million CenterPoint customers without power. Six days after the storm, some 270,000 homes and businesses in the Houston area were still without power. At a press conference on July 14, 2024, Texas Governor Greg Abbott said that he was demanding an investigation into CenterPoint's response to Hurricane Beryl. Among other comments, Governor Abbott said that CenterPoint did not have "an adequate number of workers pre-staged" before the storm hit. Following this news, CenterPoint's stock price dropped over 6% on July 15, 2024.
If you suffered a loss on your CenterPoint securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Dayforce Inc (NYSE: DAY) concerning potential violations of the federal securities laws.
On April 4, 2024, Dayforce was the subject of a report published by Blue Orca Capital. The report alleges that the Company "engages in highly aggressive revenue recognition and accounting maneuvers to inappropriately pull forward revenues and inflate profits." The report continues, "Dayforce is plagued by worst-in-class GAAP gross margins, yet its stock trades at an unjustified 25%+ premium above other human capital management companies, likely because of a latticework of misperceptions created around the Company's business and true profitability." The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
If you suffered a loss on your Dayforce securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into ServiceNow, Inc. (NYSE: NOW) concerning potential violations of the federal securities laws.
On July 8, 2024, Guggenheim downgraded ServiceNow to Sell from Neutral, opining that the Company's apparent expectations with respect to generative artificial intelligence business in the second half of 2024 were overly optimistic and that ServiceNow was overpriced relative to the future risks that the Company faces. Following this news, ServiceNow's stock price dropped over 5% on July 8, 2024.
If you suffered a loss on your ServiceNow securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into HilleVax, Inc. (NASDAQ: HLVX) concerning potential violations of the federal securities laws.
On July 8, 2024, HilleVax was the subject of a Fierce Biotech article. According to the article, "HilleVax's stock took a nosedive after the vaccine biotech's sole clinical-stage candidate failed a phase 2b trial in norovirus-related acute gastroenteritis (AGE)." The article continues, "The virus-like particle-based vaccine, dubbed HIL-214, missed all primary and secondary endpoints of the NEST-IN1 study of more than 2,800 infants aged about five months of age in the U.S. and Latin America."
If you suffered a loss on your HilleVax securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Helios Technologies, Inc. (NYSE: HLIO) concerning potential violations of the federal securities laws.
Helios formally announced on July 9, 2024, that Josef Matosevic, who serves as the Company's President, Chief Executive Officer, and Director, was placed on an immediate paid leave, effective retroactively from July 1, 2024. This administrative action arose in response to allegations suggesting a potential violation of the Company's Code of Business Conduct and Ethics. The Company has initiated an internal investigation to thoroughly examine the circumstances surrounding these allegations.
If you suffered a loss on your Helios securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into LegalZoom.com, Inc. (NASDAQ: LZ) concerning potential violations of the federal securities laws.
On July 9, 2024, after market close, LegalZoom announced the resignation and replacement of its current Chief Executive Officer. According to the announcement, “The Board and Mr. Wernikoff decided that now is the right time for this transition, as the Company increases its focus on shifting towards subscription-based revenue to drive long-term profitable growth.” LegalZoom also disclosed a reduction in revenue guidance for the full year from a range of $700 million to $720 million to a range of $675 million to $685 million. LegalZoom’s stock price opened at $5.36 per share on July 10, 2024, down approximately 30% from its market closing price of $7.85 per share on July 9, 2024.
If you suffered a loss on your LegalZoom securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Helen of Troy Limited (NASDAQ: HELE) concerning potential violations of the federal securities laws.
On July 9, 2024, before market open, Helen of Troy announced 1Q25 financial results and then reduced its revenue guidance for the 2Q and full fiscal year 2025. In pertinent part, the Company told investors that the “macro environment and the health of consumers and retailers has worsened,” causing the volume of sales to decline. Analysts questioned management over their visibility into earnings and potential problems in the future. Helen of Troy’s stock price opened at $62.00 per share compared to $89.04 per share at close on June 8, 2024.
If you suffered a loss on your Helen of Troy Limited securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Accolade, Inc. (NASDAQ: ACCD) concerning potential violations of the federal securities laws.
On June 27, 2024, Accolade reported a quarterly loss of $0.35 per share. Following the release of its earnings, shares of Accolade fell over 33% in afterhours trading.
If you suffered a loss on your Accolade securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Cibus, Inc. (NASDAQ: CBUS) concerning potential violations of the federal securities laws.
Bonitas Research ("Bonitas") issued a report on June 4, 2024, alleging that it had "found no evidence that Cibus' gene-editing technology brings desirable new crops to market." Bonitas asserted that it had found "farmer complaints of lower crop yields and lost revenues, along with multiple examples of large seed manufacturers and distributors walking away from joint ventures and partnerships with Cibus for a variety of seed types and seed traits." Following this news, Cibus's stock price dropped over 12% the same day.
If you suffered a loss on your Cibus, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Target Hospitality Corp. (NASDAQ: TH) concerning potential violations of the federal securities laws.
Target Hospitality issued a press release on June 10, 2024, announcing that it had "received notice that the U.S. government intends to terminate the existing South Texas Family Residential Center ('STFRC') services agreement with Target's migrant programming partner ('STFRC Partner'), effective in 60 days, or on or about August 9, 2024 ('Effective Date')." Target Hospitality stated that it "intends to provide operational and financial updates giving effect to the termination prior to June 30, 2024." Following this news, Target Hospitality's stock price dropped over 31% on June 11, 2024.
If you suffered a loss on your Target Hospitality securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Owens & Minor, Inc. (NYSE: OMI) concerning potential violations of the federal securities laws.
On May 3, 2024, Owens announced 1Q24 financial results that beat consensus estimates. Additionally, the Company reported Patient Direct revenue that was below expectations. Management blamed it on “unique challenges that occurred in the quarter." Analysts commenting on the missed revenue noted 2024 may be even more back-half weighted than management already guided. Following this news, Owens’s stock price fell by $6.30 per share, or approximately 26% to close at $18.21 per share.
If you suffered a loss on your Owens & Minor securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Owens & Minor, Inc. (NYSE: OMI) concerning potential violations of the federal securities laws.
Owens & Minor issued a press release on February 3, 2025, "announc[ing] selected preliminary financial results for the fourth quarter and year ended December 31, 2024 in advance of its upcoming earnings announcement and conference call." Among other items, Owens & Minor reported revenue that fell short of consensus estimates and said that it "expects to record a non-cash goodwill impairment charge within its Apria division of approximately $310 million, or approximately ($4.00) net loss per share." The Company attributed the impairment charge "to a combination of factors occurring in the fourth quarter 2024", "[t]he majority of [which] are related to financial market changes inclusive of a decline in Owens & Minor's stock price and rising interest rates." Following this news, Owens & Minor's stock price fell over 35% on the same day.
If you suffered a loss on your Owens & Minor, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Uranium Energy Corp. (NYSE: UEC) concerning potential violations of the federal securities laws.
UEC filed its quarterly report on June 10, 2024, for the quarter ended April 30, 2024 with the U.S. Securities and Exchange Commission. Among other items, UEC reported an adjusted loss per share of $0.05, missing consensus estimates. The Company also reported zero revenues and an operating loss of $13.8 million, compared to revenues of $20 million and an operating loss of $3.5 million for the same period in the prior year. Following this news, UEC's stock price dropped over 8% on June 11, 2024.
If you suffered a loss on your Uranium Energy securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into The Toro Company (NYSE: TTC) concerning potential violations of the federal securities laws.
Jehoshaphat Research published a report on May 21, 2024, alleging, among other things, that Toro "has borrowed revenues and earnings from the future by selling excessive product into its dealer channel" and that the Company "set up a cliff" in its near-term operating cash flows worth $400 million or more. Following this news, Toro's stock price dropped over 3% the same day.
If you suffered a loss on your The Toro Company securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Phreesia, Inc. (NYSE: PHR) concerning potential violations of the federal securities laws.
Phreesia issued a press release on May 30, 2024, announcing financial results for the first quarter of its fiscal year 2025. Among other items, Phreesia update its "revenue outlook for fiscal year 2025 to a range of $416 million to $426 million from a previous range of $424 million to $434 million." Phreesia advised that "[t]he updated revenue range incorporates the accelerated wind-down of a clearinghouse client relationship" and that "[t]he revenue range provided for fiscal 2025 assumes no additional revenue from potential future acquisitions completed between now and January 31, 2025." Following this news, Phreesia's stock price dropped over 7% on May 31, 2024.
If you suffered a loss on your Phreesia securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Ovid Therapeutics Inc. (NASDAQ: OVID) securities.
If you suffered a loss on your Ovid investment and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
THE LAWSUIT: Jun 26 2019 - Jun 26 2024
CASE DETAILS: Ovid issued a press release on June 17, 2024, announcing that “Takeda’s Skyline study in Dravet syndrome narrowly missed its primary endpoint of reduction in convulsive seizure frequency” and that “Takeda’s Skyway study in Lennox-Gastaut syndrome missed its primary endpoint of reduction in major motor drop seizures[.]” Following this news, Ovid’s stock price dropped over 28% on June 17, 2024.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Tripadvisor, Inc. (NASDAQ: TRIP) concerning potential violations of the federal securities laws.
On May 9, 2024, the Company hosted its quarterly earnings call. During the call, management guided toward earnings and revenue substantially below what had been previously anticipated. The Company cited changes to Google’s search algorithm and challenging comparisons to prior quarters. However, analysts suggested the guidance indicated structural problems within Tripadvisor which exist pre-Covid. Following the earnings call, TRIP shares fell $7.32, or 28.7% overnight.
If you suffered a loss on your Tripadvisor securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into EPAM Systems, Inc. (NYSE: EPAM) concerning potential violations of the federal securities laws.
On May 8, 2024, Epam updated its guidance for the full year and 2Q that was below expectations. Management blamed it on the macro environment, specifically the “demand not improving to the degree expected.” Analysts commenting on the lowered guidance noted the Company’s lack of visibility and surprise at the magnitude of the guide down. Following this news, Epam’s stock price fell by $67.27 per share, or approximately 27% to close at $181.93 per share.
If you suffered a loss on your EPAM securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Remitly Global, Inc. (NASDAQ: RELY) concerning potential violations of the federal securities laws.
On May 1, 2024, Remitly announced 1Q24 financial results which missed analysts’ revenue and gross profits as its active customer count fell short. The Company blamed it on “seasonal dynamics” and reconfirmed its revenue guidance for the full year. Analysts commenting on Remitly’s missed revenue mention management’s continual ‘back half’ weighted story that new customers will ramp up in the second half is “running thin.” Following this news, Remitly’s stock price fell by $2.14 per share, or approximately 12% to close at $15.40 per share.
If you suffered a loss on your Remitly Global, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into H&E Equipment Services, Inc. (NASDAQ: HEES) concerning potential violations of the federal securities laws.
On February 22, 2024, H&E released its Q4-2023 earnings in which the Company’s officers presented an “optimistic” outlook for the Company’s financials in 2024. H&E officers described a favorable rental environment and “sound” industry fundamentals and thus anticipated further growth. However, on April 30, 2024, the Company hosted its Q1-2024 quarterly earnings call on which H&E Officers announced reduced capital expenditure (“CapEx”) guidance. Company officers said the CapEx cut was due to reduced equipment utilization, “subdued” spending on construction projects, and persistently high interest rates. Analysts said the reduced CapEx reflects an “incrementally negative outlook” for the Company. Following the release of the earnings report, CMTL shares fell $11.25, or 19%.
If you suffered a loss on your H&E securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Stevanato Group S.p.A. (NYSE: STVN) concerning potential violations of the federal securities laws.
On May 9, 2024, Stevanato announced 1Q24 financial results that were below expectations and included a significant earnings miss for the quarter. The Company blamed the miss on higher than anticipated “industry-wide vial destocking” with no expected improvement in vial demand and lowered its guidance for fiscal year 2024. Analysts commenting on the lowered guidance mention “a mismatch of management visibility and the expectations” set by the Company relative to the reality of the market. Following this news, Stevanato’s stock price fell by $5.81 per share, or approximately 22% to close at $21.10 per share.
If you suffered a loss on your Stevanato securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Entravision Communications Corporation (NYSE: EVC) concerning potential violations of the federal securities laws.
On the evening of March 5, 2024, Entravision disclosed that Meta (Facebook) intends to wind down its authorized sales partner program, and is ending its relationship with the company. Meta accounted for roughly half of Entravision’s revenue in 2023. Following this news, shares of Entravision Communications Corp. have dropped over 48% in premarket trading.
If you suffered a loss on your Entravision Communications Corporation securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Comtech Telecommunications Corp. (NASDAQ: CMTL) concerning potential violations of the federal securities laws.
On December 7, 2023, Comtech released its earnings report for the quarter ended October 31, 2023. The report contained an “going concern” qualification due to worries about Comtech’s continued compliance with its financial covenants. The Company further revealed it had drawn down most of its credit facility and was engaged in protracted negotiations to renew that facility, set to expire in October 2024. Analysts raised alarm about Comtech’s “unbilled receivables,” an accounting practice used to recognize revenue prior to a company actually receiving those funds. One analyst described the practices as “Aggressive Accounting”. On March 18, 2024, the Company released its quarterly earnings report, days after dismissing its CEO for alleged ethics violations. The Company missed revenue projections and indicated ongoing uncertainty about its debt negotiations. Analysts also noted Comtech’s continued use of “unbilled receivables” and its impact on the Company’s financial statements. Following the release of the earnings report, CMTL shares fell $4.63, or 37%, overnight.
If you suffered a loss on your Comtech securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Domo, Inc. (NASDAQ: DOMO) concerning potential violations of the federal securities laws.
On August 24, 2023, Domo announced it was lowering its full year 2024 guidance and expected losses per share to range from 39 cents to 47 cents. The Company blamed it on heightened risk of non-renewals specifically as to its larger accounts. On an earnings call in May 2023, CFO David Jolley stated “we continue to believe we're in a good position to accelerate our billings over the first half outlook as we expect growth in our ramped sales capacity to accelerate.” Analysts commenting on the missed guidance mention Domo’s admitted mismanagement of its FY23 “ramped sales capacity.” Following this news, Domo’s stock price fell by $6.10 per share, or approximately 34% to close at $10.94 per share.
If you suffered a loss on your Domo securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






|
Vital Farms Class Action Summary |
|
|
Company |
Vital Farms, Inc. (NASDAQ: VITL) |
|
Lead Plaintiff Deadline |
May 26, 2026 |
|
Class Period |
May 8, 2025 – February 26, 2026 |
|
Stock Drop |
February 26, 2026 – VITL fell $2.68 (10.8%) to $22.11 |
|
Lawsuit Type |
Securities Class Action |
Introduction
A securities class action lawsuit has been filed against Vital Farms, Inc. (NASDAQ: VITL), its CEO Russel Diez-Canseco, and its CFO Thilo Wrede on behalf of investors who purchased Vital Farms securities between May 8, 2025 and February 26, 2026. The complaint, filed in the U.S. District Court for the Western District of Texas, alleges that defendants made materially false and misleading statements about the company's transition to a new enterprise resource planning (ERP) system, failing to disclose that the implementation would cause significant disruptions to shipments and production and result in the loss of critical retail shelf space. When Vital Farms revealed on February 26, 2026 that it had missed its own revenue guidance and was still struggling to recapture shelf space lost during the ERP transition, VITL shares fell $2.68, or 10.8%, to close at $22.11.
Company Profile
Vital Farms is the leading U.S. brand of pasture-raised eggs and butter, headquartered in Austin, Texas. The company focuses on ethical food production, animal welfare, and sustainable farming, and its common stock trades on NASDAQ under the ticker symbol VITL.
Class Period
May 8, 2025 – February 26, 2026, inclusive.
Investors who purchased or acquired Vital Farms (VITL) securities during the Class Period may be entitled to seek recovery under the federal securities laws.

Allegations
The complaint alleges that throughout the Class Period, Vital Farms and its senior executives misled investors about the risks and consequences of the company's multi-year transition to a new ERP system. Vital Farms had repeatedly disclosed that the ERP implementation was "fundamental" to its planned operational improvements and required the significant time and attention of management and key crew members. Yet according to the complaint, defendants knew or recklessly disregarded that the ERP rollout would cause material disruptions to the company's shipments and production, disruptions they failed to disclose to investors, instead presenting the risks only as hypothetical possibilities in boilerplate risk disclosures.
The alleged misrepresentations began with Vital Farms' first quarter 2025 10-Q, filed May 8, 2025, when CFO Thilo Wrede announced the ERP launch date had been pushed from summer to early fall 2025 to "ensure flawless switchover." The complaint alleges that this delay itself signaled the complexity and risk of the transition, yet defendants continued to present the implementation in optimistic terms while signing Sarbanes-Oxley certifications attesting to the accuracy of the company's financial reporting and internal controls. In the second quarter 2025 earnings call on August 7, 2025, Wrede confirmed the ERP remained on track for early fall and raised full-year 2025 revenue guidance from $740 million to $770 million, further reinforcing investor confidence in the company's trajectory.
By the third quarter 2025 earnings call on November 4, 2025, the ERP had gone live and production had already slowed. The complaint alleges defendants sought to minimize these disruptions, with Wrede characterizing the slowdown as lasting only "the first two weeks of the fourth quarter" and claiming it was "always part of our plan." Wrede further assured investors that "the business has quickly bounced back and we are now operating at pre go live shipment levels" and raised guidance again to $775 million.
According to the complaint, these statements were materially false and misleading because the production disruptions were more severe and longer-lasting than defendants acknowledged, resulting in delayed shipments during the critical holiday period that cost Vital Farms valuable retail shelf space, a consequence defendants failed to disclose.
The Truth Emerges
On February 26, 2026, before markets opened, Vital Farms filed its 2025 annual report revealing that fiscal year 2025 revenue came in at $759.4 million, missing the company's own raised guidance of $775 million. The company also reported earnings per share of $0.35, falling short of the $0.39 market consensus. The 2025 10-K acknowledged what the complaint alleges defendants had concealed for months: that Vital Farms "experienced temporary disruptions in order and fulfillment levels following the launch date of the new ERP system" in the fourth quarter of fiscal 2025.
During the accompanying earnings call, CFO Wrede admitted that "volume growth so far is lagging our initial expectations" and revealed that the company was "still recapturing shelf space" lost after "several weeks of slow shipments following our ERP implementation last year during the lead-up to the peak holiday period." CEO Diez-Canseco acknowledged the "short-term dislocation" and described ongoing efforts to rebuild retailer relationships, telling analysts the company was shifting from retailers asking "can you ship what you're talking about" to conversations about how to "grow together." These admissions directly contradicted the third quarter assurances that the business had "quickly bounced back" and that the slowdown had "no impact" on full-year guidance.
Market Reaction
Following the February 26, 2026 disclosures, Vital Farms stock declined $2.68 per share, or 10.8%, to close at $22.11. The sharp sell-off reflected the market's reassessment of the company's operational condition after learning that the ERP-related disruptions were materially worse than defendants had represented, that revenue had missed guidance, and that the company was still working to recapture lost retail shelf space months after the ERP went live.
Next Steps
· The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.
· The Court will then consider motion for class certification.
· The Court will later consider a Motion to Dismiss.
Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) concerning potential violations of the federal securities laws.
On the Q4 2025 earnings call, CEO Adam Grossman stated “ASCENIV achieved $363 million in net revenue, representing 51% year-over-year growth.” Culper Research’s short report contends ASCENIV only achieved its growth on the back of “classic channel stuffing.” ADMA’s annual report further claimed its commercial execution was “expected to accelerate demand utilization while maintaining cost discipline.” Yet, Culper contends that members of ADMA’s distributor attested that “underlying demand ‘is not really growing.’” The gap between the reported 20% revenue growth and the alleged 3% decline represents a substantial divergence. ADMA stock dropped sharply immediately following publication of the short-seller report on March 24, 2026 and throughout the following days.
If you suffered a loss on your ADMA Biologics, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






A securities fraud class action has been filed against Atara Biotherapeutics, Inc. (NASDAQ: ATRA) on behalf of investors who purchased or acquired securities between May 20, 2024 and January 9, 2026, under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5. Investors allege that the company and its executives misrepresented the regulatory prospects for tabelecleucel, a T-cell immunotherapy, by concealing manufacturing deficiencies and fundamental flaws in the clinical trial used to support approval from the U.S. Food and Drug Administration, including the accelerated approval pathway. The complaint alleges that manufacturing issues at a third-party facility and design defects in the ALLELE study made FDA approval unlikely, yet executives promoted the product's imminent approval and planned early 2025 launch. When the FDA issued two Complete Response Letters and later placed clinical holds on Atara’s active IND applications, Atara’s stock fell sharply across three separate disclosures, including declines of 40.5%, 7.91%, and 56.99%, according to the complaint.
Case Name: Jeremy Chin Zhi Kuang v. Atara Biotherapeutics, Inc., et al.
Case No.: 2:26-cv-03083
Jurisdiction: U.S. District Court, Central District of California
Filed on: March 23, 2026
Atara Biotherapeutics, a clinical-stage biopharmaceutical company develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. The company's lead product candidate is tabelecleucel (tab-cel, EBVALLO), a T-cell immunotherapy program classified as a biologic for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease, including adult and pediatric patients two years and older, with commercialization support from Pierre Fabre Médicament.
May 20, 2024 – January 9, 2026, inclusive.
All persons and entities other than Defendants that purchased or otherwise acquired Atara securities (ATRA) may be eligible to join the Atara Biotherapeutics, Inc. (ATRA) class action lawsuit, including common stock traded on NASDAQ.

The complaint names Atara Biotherapeutics, Inc. and four executives as defendants: AnhCo Thieu Nguyen (President and CEO since September 2024), Pascal Touchon (CEO during most of the class period and later Chairman), Eric Hyllengren (CFO and COO), and Yanina Grant-Huerta (Chief Accounting Officer). Investors allege these defendants promoted tabelecleucel's regulatory approval prospects for accelerated approval while concealing critical manufacturing problems at a third-party manufacturing facility and clinical trial deficiencies that made FDA approval unlikely for the EBVALLO Biologics License Application.
On May 20, 2024, as Atara submitted its Biologics License Application to the FDA for EBV+ post-transplant lymphoproliferative disease (EBV+PTLD), then-CEO Pascal Touchon called the BLA submission "a significant moment for Atara" and stated the company looked forward "to continued collaboration with the FDA on its review" and preparation "for the potential launch of this innovative therapy in the U.S." Two months later, on July 17, 2024, after the FDA accepted the BLA for priority review, Touchon described the acceptance as "a significant milestone" and said the company continued working "to help prepare for the potential launch in the U.S. in early 2025." On August 12, 2024, Touchon told investors the company was "making significant progress with the agency towards the target action date of January 15, 2025, while supporting our partner Pierre Fabre with their U.S. launch preparation." On November 12, 2024, new CEO AnhCo Thieu Nguyen characterized the first quarter of 2025 as "positioned to be transformational for the company, with the potential for FDA approval of tab-cel and transition of this business to our partner Pierre Fabre."
According to the complaint, these statements were materially false because manufacturing issues at a third-party facility and inherent deficiencies in the ALLELE study design, a single-arm trial, made FDA approval unlikely. The complaint alleges that these manufacturing problems subjected Atara to heightened regulatory scrutiny and jeopardized ongoing clinical trials, while the study defects in design, conduct, and analysis undermined the evidence needed for accelerated approval. Investors allege defendants knew or recklessly disregarded that tabelecleucel's regulatory prospects were overstated and that these issues would have a significant negative impact on the company's business and financial condition, in violation of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5.
The truth began surfacing on January 16, 2025, when Atara announced it received a Complete Response Letter from the FDA rejecting the tabelecleucel BLA, stating the application could not be approved in its present form. The company disclosed that the CRL was "solely related to observations as part of a standard pre-license inspection of a third-party manufacturing facility for EBVALLO." Five days later, on January 21, 2025, Atara revealed that the FDA had placed a clinical hold on the company's active Investigational New Drug applications due to "inadequately addressed GMP compliance issues identified during the pre-license inspection of the third-party manufacturing facility." These disclosures contradicted executives' repeated assurances about regulatory progress and launch readiness.
Nearly a year later, on January 12, 2026, the FDA issued a second Complete Response Letter, or CRL, that exposed deeper problems with the tabelecleucel application and reiterated that the BLA could not be approved in its present form. The agency stated that "the single arm ALLELE trial is no longer considered to be adequate to provide evidence of effectiveness for accelerated approval" and that "the trial's interpretability is confounded due to trial study design, conduct, and analysis." This revelation contradicted the company's longstanding representations that the ALLELE study supported approval and that launch was imminent.
The market reacted swiftly to each disclosure. On January 16, 2025, when Atara announced the first Complete Response Letter citing manufacturing facility issues, the stock price fell $5.33 per share, or 40.5%, to close at $7.83 per share. Five days later, on January 21, 2025, when the company disclosed the FDA's clinical hold due to GMP compliance issues, shares fell another $0.52 per share, or 7.91%, to close at $6.05 per share. The most severe decline occurred on January 12, 2026, when Atara revealed the second CRL stating the ALLELE trial was inadequate for approval. The stock plummeted $7.79 per share, or 56.99%, to close at $5.88 per share in a single-day move. Across these three disclosures, investors who purchased during the class period suffered substantial losses as the company's regulatory setbacks unfolded.
● The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.
● The Court will then consider motion for class certification.
● The Court will later consider a Motion to Dismiss.
Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Freshpet, Inc. (NASDAQ: FRPT) concerning potential violations of the federal securities laws.
On March 17, 2026, an NAD ruling came through after a Fast-Track SWIFT challenge, an expedited single-issue process, was brought by one of Freshpet’s competitors, The Farmer’s Dog. The Farmer’s Dog argued that three of Freshpet’s video ads included statements that necessarily imply the company’s dog food is human grade. During the review, Freshpet modified one of its ads. Following the ruling, Freshpet stated it would comply with the NAD’s recommendation. Freshpet's stock subsequently declined in mid-March 2026.
If you suffered a loss on your Freshpet, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






A securities fraud class action has been filed against Lufax Holding Ltd (NYSE: LU) and two of its executives for alleged misrepresentations in violation of Section 10(b) and Rule 10b-5 of the Securities Exchange Act of 1934, and Section 20(a) control person liability made between April 7, 2023 and January 26, 2025. Investors allege that the company repeatedly assured shareholders that its internal controls and financial reporting were effective, while certain financial results were materially misstated. In January 2025, the company disclosed that its auditor PricewaterhouseCoopers had raised significant concerns about financial disclosures and that its audit opinions for 2022 and 2023 Annual Reports could no longer be relied upon. The subsequent restatement revealed that net profit had been overstated by RMB 917.0 million for 2022 and RMB 81.4 million for 2023, causing the stock to decline by approximately 22% over three trading sessions.
Case Name: Kam Wai Mau v. Lufax Holding Ltd, et al.
Case No.: 2:26-cv-03071
Jurisdiction: U.S. District Court, Central District of California
Filed on: March 21, 2026
Lufax describes itself as a leading financial services enabler for small business owners in China, operating in retail credit and credit enablement, with headquarters in Shanghai's Pudong New District, and is a publicly traded financial technology holding company incorporated in the Cayman Islands.
April 7, 2023 – January 26, 2025, inclusive.
Investors who purchased or otherwise acquired Lufax Holding Ltd securities publicly traded on the NYSE during the Class Period and suffered damages may be eligible to join the Lufax Holding Ltd (LU) class action lawsuit, including American Depositary Shares.

According to the complaint, Lufax Holding Ltd, Chief Executive Officer Yong Suk Cho, and Chief Financial Officer David Siu Kam Choy allegedly misled investors about the effectiveness of the company's internal controls and the accuracy of its financial reporting throughout the class period, by issuing false and misleading statements and failing to disclose material adverse facts.
On April 7, 2023, when Lufax Holding Ltd filed its 2022 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission, management with the participation of the CEO and CFO concluded that disclosure controls and procedures were effective as of December 31, 2022, ensuring that information required under the Exchange Act was properly recorded, processed, summarized and reported within specified timeframes. Management further concluded that internal control over financial reporting was effective as of that date.
The following year, on April 23, 2024, management issued nearly identical assurances in the company's 2023 Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission. Once again, with the participation of the CEO and CFO, management concluded that disclosure controls and procedures were effective as of December 31, 2023, and that internal control over financial reporting was effective as of that date.
The complaint alleges these repeated assurances created a false picture of financial reliability and operational integrity, including material misstatements in financial reports. Investors allege that behind these confident statements, Lufax Holding Ltd actually lacked adequate internal controls and that certain financial results were materially misstated, in contravention of Section 10(b) and Rule 10b-5. The complaint contends that defendants' statements about the company's business, operations, and prospects were materially false and misleading and lacked a reasonable basis at all relevant times.
The alleged deception began to unravel on January 27, 2025, when Lufax Holding Ltd filed a Form 6-K current report with the U.S. Securities and Exchange Commission revealing that it had fired PricewaterhouseCoopers as its auditor. The disclosure revealed that PwC had significant concerns about Lufax Holding Ltd's financial disclosures, particularly the 2022 and 2023 Annual Reports. The concerns were serious enough that PwC stated its audit opinions for those years and those Annual Reports should no longer be relied upon. PwC disclosed that on October 25, 2024, it received information during a conversation with a then-current senior executive that raised concerns about certain possible related party transactions of the company.
The full extent of the financial misstatements became clear on February 17, 2026, when Lufax Holding Ltd filed its 2024 Annual Report on Form 20-F. Independent auditors following a re-audit found that certain line items were inaccurately recorded in the consolidated financial statements, and restated its financial results. The overstatement of total income for 2022 was RMB 493.8 million, while total income for 2023 was understated by RMB 33.3 million. These errors resulted in a decrease in net profit of RMB 917.0 million for 2022 and RMB 81.4 million for 2023. These revelations directly contradicted management's prior assurances that internal controls were effective and financial reporting was accurate.
On January 27, 2025, when news of the auditor dismissal and concerns became public, Lufax Holding Ltd ADSs fell $0.40 per ADS, a decline of 13.8%, closing at $2.49 per ADS on the NYSE. The selloff continued the following day as Lufax Holding Ltd ADSs fell a further $0.17 per ADS, down 6.82%, to close at $2.32 per ADS on January 28, 2025. On January 29, 2025, the stock declined an additional $0.06 per ADS, or 2.58%, closing at $2.26 per ADS, reflecting an approximately 22% decline across three trading sessions.
● The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.
● The Court will then consider motion for class certification.
● The Court will later consider a Motion to Dismiss.
Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






A securities fraud class action has been filed against Hercules Capital, Inc. (NYSE: HTGC), a Business Development Company (BDC), and certain executives on behalf of investors who purchased securities between May 1, 2025 and February 27, 2026 under the federal securities laws, including Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Investors allege the company and its leadership misrepresented the rigor of its due diligence processes, loan origination procedures, and portfolio valuation methods while touting disciplined underwriting as a hallmark of the business. According to the complaint, the company's deal sourcing essentially amounted to copying Google Ventures' investments, its valuation team was understaffed with inadequate oversight, and it misclassified portfolio investments to obscure software debt exposure. When these practices were revealed through an investigative report, Hercules Capital's stock price fell sharply, causing significant losses to investors.
Case Name: Hunter Hanlon Taylor v. Hercules Capital, Inc., et al.
Case No.: 3:26-cv-02465-VC
Jurisdiction: U.S. District Court, Northern District of California
Filed on: March 20, 2026
Hercules Capital is a private credit firm, headquartered in San Mateo, California, also known as a Business Development Company, which specializes in making private loans to companies through loan origination and underwriting to venture-backed portfolio investments and describes itself as the largest non-bank source of venture financing in the market. The company manages more than $5.7 billion of assets with a concentrated focus on portfolio investments across life sciences and technology in the private credit sector and focuses on life sciences investments, venture-backed technology investments, and private equity/sponsor-backed technology investments.
May 1, 2025 – February 27, 2026, inclusive.
All persons and entities that purchased or otherwise acquired Hercules Capital securities during the Class Period and were damaged thereby may be eligible to join the Hercules Capital, Inc. (HTGC) class action lawsuit.

The complaint targets Hercules Capital, Inc., Chief Executive Officer Scott Bluestein, and Chief Financial Officer Seth H. Meyer for allegedly misleading investors about the company's underwriting standards and portfolio management practices in violation of federal securities laws. Throughout the class period, the company filed quarterly reports on May 1, 2025, July 31, 2025, and October 30, 2025 stating that prospective portfolio companies were subject to completion of due diligence and final investment committee approval processes. On February 12, 2026, CEO Bluestein issued a press release emphasizing that the company was maintaining disciplined underwriting as its hallmark and remained committed to fundamental principles of disciplined credit and underwriting. That same day, the company filed its Form 10-K stating that the origination process for investments included sourcing, screening, preliminary due diligence, and deal structuring and negotiation. According to the complaint, these representations painted a picture of robust oversight and careful analysis, but the reality was starkly different because deal sourcing managers relied on other investors' due diligence by copying the Google Ventures investment list. Investors allege the company overstated the due diligence applied to its deal sourcing and loan origination, as well as to its portfolio valuation process despite a valuations team that lacked cross-team review and adequate checks, and reported misclassified portfolio investments that underrepresented its software debt exposure, which the complaint says comprised approximately 35% (about $1.5 billion) of the loan portfolio and was marked at or around part. As a result, the complaint alleges the company overstated and misrepresented its portfolio valuations, rendering defendants' positive statements about the company's business, operations, and prospects materially misleading and lacking a reasonable basis.
On February 27, 2026, Hunterbrook Media published an investigative report entitled "The Myth of Hercules Capital" based on interviews with former employees that contradicted the company's public representations and scrutinized Hercules Capital's private credit practices. According to a former Hercules analyst who worked on deal sourcing, the company's process essentially amounted to going on the website for Google Ventures and just seeing what they invest in and copying it rather than conducting independent due diligence. A former member of Hercules' finance team described the valuations team as consisting of just four people in a single reporting line responsible for dozens of companies with few checks or cross-team review, highlighting inadequate internal controls in the valuation process. The report also revealed that the company underrepresented its significant software debt exposure by assigning certain businesses that described themselves as software companies to categories outside of software, even as industry software debt was in distressed territory and while the company marked software loans at par, or about 100 cents on the dollar. These revelations directly contradicted the company's repeated assurances about disciplined underwriting, robust due diligence processes, and comprehensive sourcing methodologies that had been presented to investors throughout the class period and called into question the integrity of portfolio valuation.
On February 27, 2026, following publication of the Hunterbrook Media report, Hercules Capital's stock price fell $1.22, or 7.9%, to close at $14.21 per share on unusually heavy trading volume for HTGC, reflecting a single-day decline tied to the disclosure.
Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






A securities fraud class action has been filed against Power Solutions International, Inc. (NASDAQ: PSIX) and two of its executives in the U.S. District Court for the Northern District of Illinois, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The lawsuit covers the period from May 8, 2025 through March 2, 2026, the putative class period. Investors allege the company misrepresented its ability to capture sales demand for power systems in the data center market and minimized the costs and inefficiencies associated with ramping up manufacturing capacity to meet that demand, including understated manufacturing capacity enhancement costs. According to the complaint, while executives touted record-breaking sales growth and strong demand, the company was actually experiencing significant manufacturing inefficiencies and gross margin compression that would undermine its financial performance. When the alleged truth emerged through two alleged corrective disclosures in late 2025 and early 2026, PSIX shares fell $15.55, or 19.14%, on November 7, 2025, and $24.84, or 28.97%, on March 3, 2026, according to the complaint.
Case Name: Don Dishion v. Power Solutions International, Inc., et al.
Case No.: 1:26-cv-03149
Jurisdiction: U.S. District Court, Northern District of Illinois
Filed on: March 20, 2026
Power Solutions International, Inc., headquartered in Wood Dale, Illinois, designs, engineers, manufactures, and sells engines and power systems, including alternative-fuel, emissions-certified offerings. The company mainly sells small engines used in industrial equipment like forklifts, transportation vehicles like transit buses, micro-power systems, and power solutions for data centers, serving both stationary and mobile applications across industrial and data center markets.
May 8, 2025 – March 2, 2026, inclusive.
Investors who purchased or otherwise acquired Power Solutions securities (ticker PSIX on the NASDAQ) during the Class Period and suffered damages may be eligible to join the Power Solutions International, Inc. (PSIX) class action lawsuit.

The complaint targets Power Solutions International, Inc., along with Chief Executive Officer Dino Xykis and Chief Financial Officer Xun Li, alleging they made materially false and misleading statements and omissions about the company's business operations and prospects during the class period, in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On May 8, 2025, Xykis announced the company's "best first quarter performance in the Company's history," highlighting 42% year-over-year sales growth and a 168% increase in net income, attributing the results to "growing demand for our solutions particularly in power systems, combined with company wide operational enhancements and a continued commitment to financial discipline." Three months later, on August 7, 2025, Xykis declared the second quarter marked "the strongest sales and profit performance in our Company's history," with 74% year-over-year sales growth and 138% increase in net income, again emphasizing "strong demand for our power systems solutions" and "disciplined execution of our strategy." On November 6, 2025, the CEO announced "the highest sales in our company's history," with sales increasing 62% and net income rising 59%, underscoring "the robust demand for our power systems solutions, particularly within the data center market."
According to the complaint, these statements were misleading because they concealed critical problems beneath the surface, including material adverse facts about operating inefficiencies and manufacturing capacity, and because the positive statements allegedly lacked a reasonable basis. Investors allege the company overstated its ability to capture sales demand for power systems solutions in the data center market and understated the impact of its enhancements to manufacturing capacity, including the expected costs and the nature of related inefficiencies, such as manufacturing capacity enhancement costs and supply chain performance issues. The complaint alleges that while executives touted operational enhancements and strong execution, the company was actually struggling with significant manufacturing challenges tied to an accelerated production ramp-up for data center product lines that would severely compress gross margins and undermine the profitability of its data center business.
The truth began to surface on November 6, 2025, when Power Solutions released its third quarter 2025 financial results after the market closed and disclosed operating metrics affecting gross margin. The company revealed that gross margin had decreased 5.0% year-over-year to 23.9%, attributing the decline in part to "temporary inefficiencies related to our accelerated production ramp-up" for "key data center product lines." The company also disclosed it anticipated sales growth of only 45% for full year 2025 year-over-year, a sharp deceleration from the 74% growth reported in the second quarter and 62% growth in the third quarter. These revelations contradicted prior statements about operational enhancements and the strength of the company's strategic execution, and exposed operating inefficiencies tied to the production ramp-up.
The full extent of the problems became clear on March 2, 2026, when Power Solutions announced fourth quarter and full year 2025 financial results after the market closed. The company disclosed that gross margin had declined 8% year-over-year for full year 2025 due to "operating inefficiencies related to our accelerated production ramp-up for data center product lines." The company provided its outlook for 2026, projecting only "moderate margin improvement from the products serving data center markets." CEO Xykis admitted that "operating efficiency was impacted by the ramp up of new manufacturing capacity and increased volumes across certain product lines," and that management was "executing specific actions to improve supply chain performance and manufacturing cost structures" and was only "beginning to see measurable improvements." According to the complaint, these disclosures indicated that the manufacturing inefficiencies and margin pressures associated with the accelerated ramp-up for data center product lines were more substantial than prior statements had suggested.
Following the November 6, 2025 disclosure of Q3 2025 earnings, Power Solutions' (NASDAQ: PSIX) stock price fell $15.55, or 19.14%, to close at $65.69 per share on November 7, 2025, on unusually heavy trading volume. The damage intensified after the March 2, 2026 disclosure of Q4 and full year 2025 results, when the stock (PSIX) fell $24.84, or 28.97%, to close at $60.91 on March 3, 2026, with unusually heavy trading volume on both disclosure dates.
Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






A securities fraud class action has been filed against Coty Inc. (NYSE: COTY), a publicly traded mid-cap company in the global beauty and personal care sector listed on the New York Stock Exchange (NYSE: COTY), and two of its executives in the U.S. District Court for the Southern District of New York. The lawsuit covers investors who purchased or acquired Coty common stock between November 5, 2025, and February 4, 2026. Investors allege that the company misrepresented its growth potential for fiscal year 2026, including forward-looking guidance on like-for-like revenue and adjusted profitability, claiming business trends were improving and projecting a return to sales and profit growth in the second half of the year. In reality, the complaint alleges, defendants issued materially misleading business information in violation of federal securities laws, Coty’s Consumer Beauty segment was underperforming, margins were compressed by increased marketing investments, and its Prestige fragrance segment was experiencing slowing growth. These alleged misstatements caused investors to purchase Coty securities at artificially inflated prices before the truth emerged in early February 2026, following disappointing second quarter fiscal 2026 results and the withdrawal of prior fiscal 2026 EBITDA guidance.
Case Name: Suvega Srinivasan v. Coty Inc., et al.
Case No.: 1:26-cv-02343
Jurisdiction: U.S. District Court, Southern District of New York
Filed on: March 23, 2026
Coty Inc., together with its subsidiaries, manufactures, markets, distributes, and sells branded beauty products worldwide, and its common stock trades on the New York Stock Exchange under the ticker COTY, as a mid-cap consumer company. The company operates through two segments-Prestige and Consumer Beauty-providing fragrance, color cosmetics, and skin and body care products through prestige retailers, including perfumeries, department stores, e-retailers, direct-to-consumer websites, and duty-free shops.
November 5, 2025 – February 4, 2026, inclusive.
All investors who purchased or otherwise acquired Coty common stock during the Class Period are potentially eligible to participate in the class action, including purchasers of NYSE: COTY shares.

The complaint targets Coty Inc., Chief Executive Officer Sue Nabi, and Chief Financial Officer Laurent Mercier for allegedly misleading investors about the company’s growth prospects during fiscal year 2026 through optimistic forward-looking guidance. On November 5, 2025, CEO Sue Nabi announced in a press release and earnings call that Coty’s underlying business trends were already improving, in line to slightly ahead of expectations, particularly in Prestige. She stated the company saw tremendous potential to accelerate momentum through new brand launches, innovations, market-leading e-commerce, and globally scaled brick-and-mortar presence, and expected second quarter sales at the more favorable end of previous guidance, reinforcing the company’s forward-looking guidance narrative with a return to sales and profit growth in the second half of fiscal year 2026.
The following day, on November 6, 2025, CFO Laurent Mercier reinforced this optimism during an earnings call, stating that the company continued to expect sales (like-for-like revenue) to return to growth in the second half as sell-in and sell-out reached alignment, supported by key launches in Prestige and more favorable comparisons. He also projected adjusted EBITDA, a non-GAAP profitability metric, to return to growth in the second half, targeting around $1 billion for the year.
According to the complaint, these statements concealed material adverse facts about the true state of Coty’s business. Investors allege that the Consumer Beauty segment was actually underperforming, margins were being compressed by increased marketing investments, and the Prestige fragrance segment was experiencing slowing growth rather than the improvement executives publicly described, amounting to materially misleading disclosures under federal securities laws.
The alleged deception began to unravel on February 4, 2026, when newly appointed Interim CEO Markus Strobel delivered prepared remarks acknowledging that Coty’s financial results in the past 18 months had been disappointing. He admitted that the company’s performance versus the market had been inconsistent, and in the second quarter, sell-out was flat, underperforming the market by several points in the critical fragrance category. Strobel conceded that while Coty had outstanding assets and capabilities, the company had not been delivering at the level it should.
The next day, on February 5, 2026, Coty announced its second quarter results and issued a press release revealing disappointing earnings and a like-for-like revenue decline of approximately 3% in the quarter with worsening performance in the Consumer Beauty segment. The company withdrew its prior fiscal year 2026 guidance for EBITDA and free cash flow and provided guidance solely for Q3 due to what CFO Laurent Mercier described as operational discipline that had slipped across the organization over the past two years. These revelations directly contradicted the executives’ prior statements about improving business trends and returning to growth.
Investors reacted swiftly to these disclosures, with NYSE: COTY shareholders seeing sharp losses. After the market closed on February 4, 2026, following Strobel’s prepared remarks, Coty’s common stock declined from a closing price of $3.43 per share to $3.15 per share on February 5, 2026 on the New York Stock Exchange, a drop of approximately 8%. The decline accelerated after Coty’s formal earnings announcement and guidance withdrawal. On February 6, 2026, the stock fell further to $2.66 per share, an additional 16% decline from the previous day’s close. Over the two-day period from February 4 to February 6, 2026, Coty’s stock price fell a total of $0.77 per share, representing a decline of approximately 22%.
● The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.
● The Court will then consider motion for class certification.
● The Court will later consider a Motion to Dismiss.
Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






A securities fraud class action has been filed under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 against Kyndryl Holdings, Inc. (NYSE: KD) covering August 1, 2024 through February 9, 2026. Investors allege the company misstated its financial results and downplayed serious internal control problems while assuring the market that any control issues did not cause misstatements-and later that controls were effective. On February 9, 2026, Kyndryl announced it could not timely file its quarterly report (Form 10-Q for Q3 FY2026, ended December 31, 2025), disclosed an investigation by the SEC Division of Enforcement into cash management and related disclosures, and admitted material weaknesses in internal control over financial reporting including information and communication and tone at the top, saying prior control effectiveness conclusions should not be relied upon. The news hit hard. Kyndryl's stock fell $12.90 per share, or 55%, to close at $10.59 on February 9, 2026, wiping out about $3 billion in market capitalization.
“Most KD shareholders never file or join the class action, which means they miss out on potential recovery funds,” said Attorney Joseph Levi.
Case Name: Brander v. Kyndryl Holdings, Inc. et al.
Case No.: 1:26-cv-00782
Jurisdiction: U.S. District Court, Eastern District of New York
Filed on: February 11, 2026
Kyndryl is a technology services company that provides infrastructure services, focused on enterprise IT infrastructure services and operating in more than 60 countries. The company describes itself as engaging in the provision of infrastructure services and is incorporated in Delaware, and its common stock trades on the NYSE under ticker KD.
August 1, 2024-February 9, 2026, inclusive.
All persons or entities who purchased or otherwise acquired publicly traded Kyndryl securities on the New York Stock Exchange (NYSE: KD) during the Class Period may be eligible to join the Kyndryl Holdings, Inc. (KD) class action lawsuit.

The complaint targets Kyndryl Holdings, Inc. and senior executives Martin J. Schroeter (Chief Executive Officer and Chairman), David B. Wyshner (Chief Financial Officer during the period), and Vineet Khurana (Senior Vice President, Global Controller, and Principal Accounting Officer), and alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5.
According to investors, the defendants told the market that control issues were contained and did not cause misstatements, and later asserted that controls were effective-assurances that allegedly concealed the true scope of internal control failures and misstated financials, and failed to disclose material weaknesses in internal control over financial reporting.
The story begins on August 7, 2024, when CEO Schroeter and CFO Wyshner signed Kyndryl's 1Q25 Form 10-Q acknowledging a material weakness in information technology general controls and stating disclosure controls were not effective. Yet they told investors that "These control deficiencies did not result in a misstatement to the annual or interim consolidated financial statements." During this period, the company emphasized free cash flow and adjusted free cash flow in its investor communications. They repeated the same message in the 2Q25 Form 10-Q on November 7, 2024, and again in the 3Q25 Form 10-Q on February 6, 2025.
The tone shifted in 2025. On May 30, 2025, in the 2025 Form 10-K, Schroeter and Wyshner concluded that as of March 31, 2025, Kyndryl's internal control over financial reporting was effective and that disclosure controls were effective, asserting compliance with disclosure controls and procedures under the Securities Exchange Act. They maintained that position into fiscal 2026, stating in the 1Q26 Form 10-Q on August 5, 2025, and the 2Q26 Form 10-Q on November 5, 2025, that disclosure controls and procedures were effective at those quarter-ends. Meanwhile, investors allege a different reality.
The complaint asserts that Kyndryl's financial statements during the Class Period were materially misstated; that the company lacked adequate internal controls and at times understated internal control issues, including deficiencies in cash management practices; and that these problems were so significant the company would be unable to timely file its Form 10-Q for the quarter ended December 31, 2025 (Q3 FY2026). As a result, the complaint alleges defendants' statements about Kyndryl's business, operations, and prospects were false and misleading or lacked a reasonable basis, constituting material misstatements and omissions actionable as securities fraud.
The truth surfaced on February 9, 2026, when Kyndryl filed a Notification of Late Filing (Form 12b-25) and a Current Report on Form 8-K, with the Securities and Exchange Commission, following the February 5, 2026 departures of its CFO, General Counsel, and Controller. The company disclosed it could not timely file its quarterly report (Form 10-Q for Q3 FY2026, ended December 31, 2025) and that the SEC's Division of Enforcement had made voluntary document requests regarding cash management practices, related disclosures-including the drivers of its adjusted free cash flow metric-and the efficacy of internal control over financial reporting.
Through its Audit Committee, Kyndryl announced a review of those areas , including an internal accounting review of cash management practices, disclosure controls, and free cash flow metrics and "certain other matters." That same day, management admitted it anticipated reporting material weaknesses in internal control over financial reporting for the quarter to be reported, for the full fiscal year ended March 31, 2025, and for the first two fiscal quarters of fiscal 2026 (Q1 and Q2 FY2026). The weaknesses were expected to include controls related to information and communication and tone at the top, and Kyndryl stated that its prior assessment of internal control effectiveness as of March 31, 2025 should no longer be relied upon. These admissions directly contradicted earlier assurances that controls were effective and that identified deficiencies had not resulted in misstatements.
Before the market opened on February 9, 2026, investors learned of the late filing and SEC investigation, and by the close Kyndryl's stock had fallen $12.90 per share, or 55%, to finish at $10.59, a single-day decline on NYSE: KD that erased approximately $3 billion in market capitalization. The sharp, same-day drop followed Kyndryl's disclosures of its late filing, SEC document requests regarding cash management and related disclosures, and its anticipation of material weaknesses in internal control over financial reporting.
The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.
The Court will then consider motion for class certification.
The Court will later consider a Motion to Dismiss.
Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.
The lawsuit alleges that Kyndryl Holdings, Inc. (NYSE: KD) and certain executives violated federal securities laws by making materially false and misleading statements about the company's internal controls and financial reporting. According to the complaint, the company downplayed issues with its internal control over financial reporting and issued consolidated statements of cash flows that were allegedly materially misstated. The lawsuit was filed in the U.S. District Court for the Eastern District of New York on February 11, 2026.
The class period covers investors who purchased or otherwise acquired publicly traded Kyndryl securities between August 7, 2024 and February 9, 2026, inclusive. Investors who acquired Kyndryl common stock (NYSE: KD) during this timeframe and suffered losses may be eligible to participate in the class action, subject to court certification and other legal requirements.
The complaint names the following defendants:
Kyndryl Holdings, Inc. (the company)
Martin J. Schroeter, Chief Executive Officer and Chairman of the Board
David B. Wyshner, former Chief Financial Officer
Vineet Khurana, former Senior Vice President, Global Controller, and Principal Accounting Officer
According to the lawsuit, Defendants Wyshner and Khurana departed from their positions in connection with the events described in the complaint.
On February 9, 2026, Kyndryl filed a Notification of Late Filing with the SEC, announcing it could not timely file its quarterly report. The filing revealed an SEC investigation into the company's cash management practices and related disclosures. The company also disclosed anticipated material weaknesses in internal controls, including issues related to "information and communication and tone at the top." According to the complaint, Kyndryl's stock price fell $12.90 per share, or 55%, closing at $10.59 on February 9, 2026.
The complaint asserts claims under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder against all defendants. Additionally, the lawsuit asserts claims under Section 20(a) of the Exchange Act against the individual defendants as alleged "controlling persons" of the company. Plaintiffs seek compensable damages caused by the alleged violations of federal securities laws.
The complaint alleges that Kyndryl's statements about its disclosure controls and internal controls over financial reporting were materially false and misleading. According to the lawsuit, while the company disclosed deficiencies related to information technology general controls (ITGCs), it allegedly downplayed broader issues with internal controls. The February 2026 disclosure indicated anticipated material weaknesses related to "information and communication and tone at the top" affecting multiple reporting periods.
The lawsuit seeks class action certification, compensatory damages for class members who purchased Kyndryl securities during the class period and were damaged thereby, reasonable costs and expenses including counsel fees and expert fees, and such other relief as the court may deem appropriate. A jury trial has been demanded.
The lawsuit alleges Kyndryl Holdings (NYSE: KD) and certain executives made false statements about the company's internal controls and financial reporting. The complaint claims consolidated cash flow statements were materially misstated during the class period from August 7, 2024 to February 9, 2026.
The class period is August 7, 2024 through February 9, 2026. Investors who purchased Kyndryl common stock during this period and suffered losses may be eligible to participate in the class action.
According to the complaint, Kyndryl's stock fell 55% on February 9, 2026, after the company disclosed it could not timely file its quarterly report and revealed an SEC investigation into its cash management practices and anticipated material weaknesses in internal controls.
The defendants are Kyndryl Holdings, Inc., CEO Martin J. Schroeter, former CFO David B. Wyshner, and former Controller Vineet Khurana. The complaint alleges the individual defendants were controlling persons of the company.
The complaint alleges violations of Section 10(b) and Rule 10b-5 of the Securities Exchange Act against all defendants, and Section 20(a) claims against the individual defendants as alleged controlling persons.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






A federal securities fraud class action has been filed against Picard Medical, Inc. (NASDAQ: PMI) under the Securities Exchange Act of 1934, including Rule 10b-5 and Sections 10(b) and 20(a) on behalf of investors who bought Picard securities between September 2, 2025 and October 31, 2025. Investors allege defendants misled the market by omitting that Picard's stock was being driven by a fraudulent social media promotion scheme targeting retail investors that used impersonated financial professionals, and concealed artificial trading activity.
Behind the upbeat messaging, public reports later described an artificial buying frenzy fueled by false online claims and coordinated trading. When these reports surfaced and volatility spiked, the company stated it was not aware of any undisclosed material change, omitting mention of false rumors and manipulation. Investors say they were harmed when the stock crashed to $3.99 on October 24, 2025, a single-day 70% decline, and then continued falling to approximately $2.00 per share.
“Most PMI shareholders never file or join the class action, which means they miss out on potential recovery funds,” said Attorney Joseph Levi.
Case Name: Louie v. Picard Medical, Inc. et al.
Case No.: 5:26-cv-01024
Jurisdiction: U.S. District Court, Northern District of California, San Jose Division
Filed on: February 2, 2026
Picard is a holding company that owns SynCardia Systems, LLC, based in Tucson, Arizona, a medical technology business that manufactures and sells the only U.S. Food and Drug Administration and Health Canada approved implantable total artificial heart, the SynCardia TAH artificial heart. The company operates in the U.S., Europe, and China, as a medical device manufacturer and reports work on a next-generation fully implantable total artificial heart, with an FDA-approved product line.
September 2, 2025-October 31, 2025, inclusive.
All persons and entities that purchased or otherwise acquired Picard securities during the Class Period, including common stock trading under the ticker symbol PMI may be eligible to join the Picard Medical, Inc. (PMI) class action lawsuit.
According to the complaint, the lawsuit targets Picard Medical, Inc.; CEO Patrick NJ Schnegelsberg; CFO Bernard Skaggs; Matt Schuster; directors Yuncai "Richard" Fang and Chris Hsieh; underwriters Westpark Capital, Inc., Sentinel Brokers Company, Inc., R.F. Lafferty & Co. Inc., and American Trust Investments; and auditor MaloneBailey, LLP. Investors allege defendants presented a positive picture of Picard's business and stock while omitting the artificial trading and online promotion allegedly propelling the share price, constituting material misstatements and omissions under Sections 10(b) and 20(a) of the Securities Exchange Act.
The story begins on September 2, 2025, when Picard's IPO prospectus told investors it owns SynCardia, which "manufactures and sells the only U.S. Food and Drug Administration and Health Canada approved implantable total artificial heart." On September 15, 2025, Patrick NJ Schnegelsberg issued a press release touting second-quarter strength, citing "over 200% revenue growth year-over-year," improved operations, and IPO proceeds to fund development and expansion that allegedly lacked a reasonable basis. As the stock rose into late October, the company continued to speak positively about operations and prospects and omitted material risk disclosures about stock promotion and market manipulation.
Then, on October 24, 2025, after volatility spiked, the company released a statement asserting it was "not aware of any undisclosed material change in the Company's operations or financial condition" to account for the stock's swings. The complaint alleges that, during the Class Period, defendants' public statements and risk disclosures omitted that Picard's stock was the subject of a fraudulent stock promotion campaign and artificial trading activity.
Behind the scenes, investors allege a coordinated social-media-based promotion, a pump-and-dump scheme used impersonated financial professionals to spread sensational but baseless claims, creating a retail buying frenzy. The complaint further alleges that insiders and/or affiliates used offshore or nominee accounts during the price inflation campaign to execute coordinated insider share dumping. As a result, the complaint claims defendants' positive statements about Picard's business, operations, and prospects were materially misleading and lacked a reasonable basis that manufactured demand and artificially inflated the stock price.
According to the complaint, on October 23, 2025, investigations and public reports described how Picard had become the subject of an illicit social-media-driven promotion spreading false rumors and social media misinformation that artificially inflated its stock price, with touts from impersonators in online forums and chat groups as the market learned the truth about the company's trading activity. Despite warning signs and public reports of manipulation as early as September 30, 2025, the company had not issued investor warnings before the crash or disclosed artificial trading activity.
The next day, on October 24, 2025, Picard addressed the volatility but said it was not aware of any undisclosed material changes in operations or finances that would explain the price moves while continuing to omit material adverse facts about the promotion scheme. These revelations and responses contradicted the company's prior optimism and its omission of manipulation risks from its public statements and stock price manipulation.
The market moved in stages. In the weeks after the September 2, 2025 IPO, Picard's share price surged from $4.00 to an intraday high of $13.68, and on October 23, 2025, it closed at $13.20. After the October 23 close, during aftermarket trading, the stock abruptly fell; by October 24, 2025, it had crashed to $3.99 per share, reflecting a single-day 70% stock price crash, and subsequently declined to approximately $2.00 per share.
The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.
The Court will then consider motion for class certification.
The Court will later consider a motion to dismiss.
Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Introduction to Aquestive Therapeutics, Inc. (AQST) Securities Class Action Lawsuit
A securities fraud class action has been filed under the federal securities laws against Aquestive Therapeutics, Inc. (NASDAQ: AQST) and its CEO Daniel Barber on behalf of investors who purchased Aquestive securities traded on the NASDAQ under ticker AQST between June 16, 2025 and January 8, 2026. Investors allege that defendants misrepresented the status of the company's New Drug Application for Anaphylm, a sublingual film epinephrine treatment for anaphylaxis, repeatedly assuring shareholders that the U.S. Food and Drug Administration approval process was on track for January 31, 2026, the PDUFA action date. In reality, the complaint alleges, Aquestive concealed or minimized significant deficiencies related to human factors-including packaging, use, administration, and labeling-that would ultimately prevent approval. When the FDA disclosed these deficiencies in January 2026 and issued a Complete Response Letter rejecting the application, Aquestive's stock price collapsed, falling over 37% in a single day.
Aquestive Therapeutics, Inc. (AQST) Securities Lawsuit Case Details
Case Name: Vincent Modica v. Aquestive Therapeutics, Inc., et al.
Case No.: 3:26-cv-02317
Jurisdiction: U.S. District Court, District of New Jersey
Filed on: March 5, 2026
Aquestive Therapeutics, Inc. (AQST) Company Profile
Aquestive Therapeutics is a pharmaceutical company based in Warren, New Jersey, and publicly traded on the NASDAQ committed to advancing medicines through innovative science and delivery technologies, including its PharmFilm oral drug delivery platform. The Company’s pipeline includes treatments for neurologic conditions such as epilepsy. One of the company's key pharmaceuticals is Anaphylm, an allergic reaction treatment that is a sublingual film formulation of epinephrine, also known as AQST-109, designed for emergency treatment of severe allergic reactions.
Aquestive Therapeutics, Inc. (AQST) Securities Lawsuit Class Period
June 16, 2025 – January 8, 2026, inclusive.
All investors who purchased or otherwise acquired Aquestive securities during the Class Period, including NASDAQ-listed AQST common stock, may be eligible to join the Aquestive Therapeutics, Inc. (AQST) class action lawsuit.

Allegations in the Aquestive Therapeutics, Inc. (AQST) Securities Class Action Lawsuit
The complaint targets Aquestive Therapeutics, Inc. and its CEO Daniel Barber for allegedly misleading investors about the regulatory approval timeline for Anaphylm, a device-free sublingual film epinephrine treatment designed for anaphylaxis. On June 16, 2025, CEO Barber announced the FDA's acceptance of the company's New Drug Application, the Anaphylm NDA, declaring that Anaphylm represented "a breakthrough in anaphylaxis treatment" and emphasizing its convenience as a product "thinner than a credit card" that required no special storage. He stated the company was "one step closer to getting this life-saving innovation in the hands of the patients and caregivers who need it most." During this period, defendants continued to express confidence in the approval process. On August 11, 2025, Barber announced preparations for "a potential U.S. launch in 2026" with "regulatory progress on track." The following day, during an earnings call, he told investors the company was "now less than 6 months away" from the FDA action date and assured them: "I'm pleased to tell you this morning that we are on track across the important elements of Anaphylm. We are on track in our FDA review process." On November 5, 2025, after the FDA decided not to convene an Advisory Committee, Barber stated that this decision "further advances our regulatory path" and that the NDA "remains on track for the scheduled January 31, 2026 PDUFA goal date," a PDUFA action date that investors watched closely.
According to the complaint, defendants created the false impression that Aquestive was on track to receive approval for Anaphylm by the January 31, 2026 PDUFA date while concealing or minimizing the significance of human factors deficiencies involving the drug's packaging, use, administration, and labeling, deficiencies in the NDA that precluded labeling discussions and post-marketing commitments. The lawsuit alleges that the FDA had identified deficiencies preventing approval discussions and raising approvability concerns, which meant approval could not be granted without remediation. These material omissions caused investors to purchase Aquestive securities at artificially inflated prices throughout the class period.
The Truth Emerges
On January 9, 2026, Aquestive disclosed that the company had received an FDA letter identifying deficiencies in the NDA that precluded discussion of post-marketing commitments, effectively halting approval and labeling discussions. The announcement stated that although the notification did not specify the deficiencies, the FDA's concerns prevented the approval process from moving forward, and the company was working to understand and resolve the issues. Less than a month later, on February 2, 2026, Aquestive announced that the FDA had issued a Complete Response Letter on January 30, 2026, one day before the January 31 PDUFA action date, formally rejecting the Anaphylm application. The CRL cited specific deficiencies in the Anaphylm human factors validation study, including instances of difficulty opening the pouch and incorrect film placement, which the FDA believed could cause significant safety issues in the setting of anaphylaxis.
These revelations directly contradicted defendants' repeated assurances throughout the class period that the approval process was on track and progressing smoothly toward the January 31, 2026 deadline. The disclosure exposed that significant regulatory obstacles existed well before the PDUFA date, undermining the optimistic narrative defendants had presented to investors about the drug's imminent approval and commercial launch.
Market Reaction
The market reacted swiftly to the January 9, 2026 disclosure of FDA deficiencies. Aquestive's common stock on the NASDAQ fell from a closing price of $6.21 per share on January 8, 2026 to $3.91 per share on January 9, 2026, a decline of $2.30 or over 37% in a single day.
Next Steps
● The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.
● The Court will then consider motion for class certification.
● The Court will later consider a Motion to Dismiss.
Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Introduction to Gartner, Inc. (IT) Securities Class Action Lawsuit
A securities fraud class action has been filed, alleging violations of the federal securities laws, including the Securities Exchange Act of 1934, Section 10(b) and Rule 10b-5 and Section 20(a) against Gartner, Inc. (NYSE: IT) and two of its executives on behalf of investors who purchased Gartner common stock on the New York Stock Exchange, ticker NYSE: IT, between February 4, 2025, and February 2, 2026. Investors allege that the company misrepresented its ability to achieve accelerating contract value growth rates and meet consulting revenue targets through materially false and misleading statements and material omissions in public financial disclosures despite ongoing industry challenges. The truth allegedly emerged in two phases during 2025 and early 2026, when Gartner disclosed significant declines in contract value growth and consulting segment shortfalls that contradicted optimistic projections and prior forward-looking revenue guidance. These revelations resulted in a cumulative decline of approximately 48% across two disclosure dates, an event-driven stock price decline that investors attribute to corrective disclosures.
Gartner, Inc. (IT) Securities Lawsuit Case Details
Case Name: Kevin Schmidt v. Gartner, Inc., et al.
Case No.: 3:26-cv-00394
Jurisdiction: U.S. District Court, District of Connecticut
Filed on: March 17, 2026
Gartner, Inc. (IT) Company Profile
Gartner is a global company operating in the information technology research and advisory sector that provides technology and business insights to its clientele through guidance, tools, conferences, and direct consulting, and is listed on the New York Stock Exchange (NYSE) as NYSE: IT. The Company operates through three segments: Business and Technology Insights, Conferences, and Consulting, generating $6.5 billion in revenue for full year 2025, as reflected in its Q4 2025 financial results.
Gartner, Inc. (IT) Securities Lawsuit Class Period
February 4, 2025-February 2, 2026, inclusive, the putative class period under federal securities laws
All investors who purchased or otherwise acquired Gartner common stock (NYSE: IT) during the Class Period may be eligible to join the Gartner, Inc. (IT) class action lawsuit.

Allegations in the Gartner, Inc. (IT) Securities Class Action Lawsuit
The complaint targets Gartner, Inc., Chief Executive Officer and Chairman Eugene A. Hall, and Executive Vice President and Chief Financial Officer Craig W. Safian for allegedly misrepresenting the company's growth prospects and operational capabilities to investors throughout the class period through materially false and misleading statements and material omissions in their public financial disclosures.
On February 4, 2025, Safian announced during an earnings call that the company's guidance and forward-looking revenue forecast reflected contract value continuing to accelerate during 2025, stating that with 12% to 16% research CV growth, the company would deliver double-digit revenue growth, which investors allege was a misleading statement.
During the same earnings call, Hall reinforced this optimistic outlook, explaining that over the course of 2025 and when exiting the year, he expected CV growth to exceed 7.8% and continue accelerating first to double digits and then to the medium-term objective of 12% to 16%, which, investors allege, artificially inflated the stock price. The company maintained this confident stance throughout the following months, including in SEC disclosures and investor communications.
On May 6, 2025, Hall announced that first quarter financial results were ahead of expectations with contract value growing 7%, and assured investors that the company would continue to provide significant value to clients and emerge from the current environment even stronger, which plaintiffs allege omitted adverse information about the Consulting segment's ability to meet internal targets. He reiterated expectations to reaccelerate CV growth to the target of 12% to 16% when the macroeconomic environment returned to normal, a forward-looking statement that plaintiffs challenge.
By November 4, 2025, Hall told investors during an earnings call that the selling environment with tariff-impacted companies was starting to improve, suggesting there was more tariff certainty and clients were focused on how to deal with it, statements investors allege concealed persisting headwinds to contract value growth.
According to the complaint, these statements concealed that Gartner was not truly equipped to handle ongoing challenges in its industry to either meet consulting revenue targets or to increase or even maintain its CV growth rate, in violation of federal securities laws. The company's repeated claims of being able to achieve 12-16% CV growth rates in a normal macroeconomic environment allegedly proved to be unrealistic, causing investors to purchase Gartner securities at artificially inflated prices and, as a result, investors suffered losses.
The Truth Emerges
The truth began to surface on August 5, 2025, when Gartner announced, in a corrective disclosure to the market, a surprising decline in its CV growth rate during its second quarter fiscal 2025 earnings release and call, which investors identify as the first corrective disclosure. The company revealed that overall CV growth had declined from 7% the previous quarter to only 5%, while CV growth excluding the U.S. federal government had similarly dropped from 8% to merely 6%. Hall acknowledged during the earnings call that the company had a high degree of confidence in what caused these headwinds because they tracked the reason for every loss for both renewals and potential new business, identifying the largest headwind as being with the U.S. federal government.
The full truth finally emerged on February 3, 2026, when Gartner again announced a significant decline in its CV growth rate, as part of its Q4 2025 financial results, which had faltered another 2% both including and excluding federal contracts. For the first time, the company disclosed a significant shortfall of its Consulting segment's performance against internal projections, reporting fourth quarter consulting revenue of $134 million compared with $153 million in the year ago period, and provided a 2026 outlook with a 2026 revenue forecast below analyst expectations. Fourth quarter contract value grew only 1% year-over-year, while CV outside the U.S. federal government grew just 4%, and its 2026 revenue guidance was below consensus analyst expectations. These revelations directly contradicted the company's prior assurances about accelerating CV growth and the ability to meet consulting segment targets.
Market Reaction
The market reacted sharply to these disclosures, with a significant stock price decline on each announcement date. On August 5, 2025, following the earnings call that revealed declining CV growth rates, Gartner's stock price on the New York Stock Exchange fell from a closing price of $336.71 per share on August 4, 2025, to $243.93 per share, a decline of $92.78 or approximately 27.55%, a single-day stock drop consistent with event-driven securities litigation.
The damage continued on February 3, 2026, when the company announced further CV decline and consulting segment shortfalls. The stock fell from a closing price of $202.40 per share on February 2, 2026, to $160.16 per share, a decline of $42.24 or nearly 20.87% in one day, and the stock closed lower following the earnings announcement.
Next Steps
● The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.
● The Court will then consider motion for class certification.
● The Court will later consider a Motion to Dismiss.
Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






|
Lead Plaintiff Deadline |
May 15, 2026 |
|
Company |
Grocery Outlet Holding Corp. (NASDAQ:GO) |
|
Eligible Securities |
All Grocery Outlet Securities |
|
Class Period |
August 5, 2025-March 4, 2026 |
|
Allegations Overview |
Defendants misrepresented the sustainability of financial growth, concealing that rapid store expansion was unsustainable and that the Restructuring Plan required further optimization including significant store closures. |
|
GO Trigger Events |
March 4, 2026 – Grocery Outlet announced Q4 and full fiscal year 2025 results that missed guidance on nearly every major financial metric, revealed an Optimization Plan including the closure of 36 financially underperforming stores, recognized $110 million in non-cash long-lived asset impairment charges, and recorded a $149.0 million non-cash goodwill impairment. CEO Jason Potter admitted on the earnings call "it's clear now that we expanded too quickly, and these closures are a direct correction." |
|
GO Stock Impact |
March 5, 2026 – Grocery Outlet's stock price fell $2.45, or 27.9%, to close at $6.34 per share on unusually heavy trading volume. |
A securities fraud class action under the federal securities laws has been filed against Grocery Outlet Holding Corp. (NASDAQ: GO) and two of its executives on behalf of investors who purchased company securities between August 5, 2025 and March 4, 2026.
Investors allege that the company and its officers misrepresented the sustainability of its financial growth, claiming strong performance driven by new store openings while concealing that the company had expanded too quickly and that its purported growth was artificially supported by unsustainable rapid expansion. On March 4, 2026, Grocery Outlet disclosed it was closing 36 underperforming stores as part of an Optimization Plan and taking $110 million in non-cash impairment charges, with CEO Jason Potter admitting "it's clear now that we expanded too quickly, and these closures are a direct correction."
Following this disclosure, the company's stock price fell 27.9% in a single trading session, causing significant losses to investors.
“Most GO shareholders never file or join the class action, which means they miss out on potential recovery funds,” said Attorney Joseph Levi.
Case Name: Jones v. Grocery Outlet Holding Corp.
Case No.: 3:26-cv-02291
Jurisdiction: U.S. District Court, Northern District of California
Filed on: March 16, 2026
Grocery Outlet Holding Corp., headquartered in Hayward, California, operates as a value retailer of consumables and fresh products (consumer staples sector) sold through independently operated stores across 16 states in the U.S., and is publicly traded on the NASDAQ as GO.
August 5, 2025-March 4, 2026, inclusive.
All persons and entities that purchased or otherwise acquired Grocery Outlet (NASDAQ: GO) securities during the Class Period and were damaged thereby may be eligible to join the Grocery Outlet Holding Corp. (GO) class action lawsuit. Excluded are the defendants, company officers and directors, members of their immediate families, and entities in which defendants have or had a controlling interest.

The complaint targets Grocery Outlet Holding Corp., along with Chief Executive Officer Jason Potter and Chief Financial Officer Christopher M. Miller, alleging they made materially false and misleading statements about the company's business operations and growth strategy during the class period, in violation of the federal securities laws. According to investors, defendants portrayed the company's financial performance as strong and sustainable while concealing fundamental problems with their expansion strategy, creating a false impression of reliable financial information.
On August 5, 2025, Grocery Outlet announced that net sales increased 4.5% to $1.18 billion during the second quarter due to new store sales and a 1.1% increase in comparable store sales, stating the company had opened 11 new stores and closed two stores to end the quarter with 552 stores in 16 states. The company also announced that the actions under its Restructuring Plan were substantially completed in the second quarter of fiscal 2025.
The company continued its positive narrative, and on the November 4, 2025 Q3 2025 earnings call the CEO told investors adjusted EPS exceeded guidance while omitting GAAP EPS, which was $0.12, 43% below consensus, versus adjusted EPS of $0.21, reporting that net sales increased 5.4% versus the prior year to $1.17 billion due to new store sales and a 1.2% increase in comparable store sales, announcing it had opened 13 new stores and closed two stores to end the quarter with 563 stores in 16 states.
Throughout this period, investors allege that defendants failed to disclose that the company had expanded too quickly into new stores, that its purportedly strong financial and operational growth was being artificially supported by excessive rapid store expansion, and that the company was unable to achieve the sustainable growth required to meet its previously set guidance, thereby minimizing the risks associated with rapid over-expansion.
The complaint further alleges that defendants concealed that the company's Restructuring Plan would require further optimization to achieve its operational goals, including significant store closures and substantial asset write-downs, and that a December 3, 2025 Form 8-K stated there was no update to the November 4 outlook, which investors allege was a material omission in light of later-announced closures.
On March 4, 2026, after the market closed, Grocery Outlet announced results for the fourth quarter and full fiscal year 2025 that missed guidance on nearly every major financial metric, and issued FY2026 profit guidance below analyst expectations. The company revealed it was adding an "optimization plan" on top of its "restructuring plan" and was "reshaping its new store growth strategy," including the closure of 36 financially underperforming stores.
The company disclosed it had determined that the long-lived assets of these closure stores were impaired and recognized $110 million in non-cash charges, and also recorded a $149.0 million non-cash goodwill impairment and reported an operating loss of $221.7 million for fiscal year 2025. During the earnings call, CEO Jason Potter admitted "it's clear now that we expanded too quickly, and these closures are a direct correction."
These disclosures undercut the Company's earlier portrayal of strong, sustainable performance driven by rapid new store openings and of a Restructuring Plan said to be substantially completed, by revealing that the Company had expanded too quickly and would need further optimization, including significant store closures and asset write-downs.
On March 5, 2026, following the previous day's after-market earnings announcement and revelations, Grocery Outlet's (NASDAQ: GO) stock price fell $2.45, or 27.9%, to close at $6.34 per share on unusually heavy trading volume, and analysts downgraded the stock following the announcement. The single-day decline came as investors reacted to Grocery Outlet's disclosure that it would close 36 financially underperforming stores and the recognition of $110 million in non-cash impairment charges, along with CEO Jason Potter's admission that "it's clear now that we expanded too quickly, and these closures are a direct correction."
● The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.
● The Court will then consider motion for class certification.
● The Court will later consider a Motion to Dismiss.
Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Levi & Korsinsky notifies investors that it has commenced an investigation into Insulet Corporation (NASDAQ: PODD) concerning potential violations of the federal securities laws.
During that same February 18 earnings call, McEvoy stated that "strong clinical evidence and real-world outcomes continue to earn prescriber and patient confidence" and described Omnipod 5 as the "favorite pump" for both type-1 and type-2 users in 2025. CFO Flavia Pease added that U.S. revenue growth was "above the high end of our guidance range, driven by continued demand for Omnipod 5 across type 1 and type 2 customers." At no point during the call did any executive reference a product-quality issue, a pending regulatory action, or an anticipated recall. Only a few weeks later, the March 12 filing revealed a defect affecting Omnipod 5 Pods. The filing identified insulin leakage capable of causing diabetic ketoacidosis -- a serious medical emergency. The Company's February 18 statements about Omnipod reliability, patient confidence, and demand-driven growth had not referenced any of these issues.
If you suffered a loss on your Insulet Corporation securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






A securities fraud class action has been filed against ChowChow Cloud International Holdings Limited (NYSE American: CHOW), whose ordinary shares trade on the NYSE American under ticker symbol CHOW and several individual officers, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 during the period from September 16, 2025, through December 10, 2025, beginning with its Initial Public Offering (IPO).
Investors allege the company made materially false and misleading statements about its business operations and prospects while failing to disclose that its stock was the subject of a pump-and-dump market manipulation and fraudulent promotion scheme involving social-media based misinformation and impersonators posing as financial professionals. The alleged scheme culminated on December 10, 2025, when the stock price collapsed 84.3% in a single trading session following two trading halts by NYSE American. Investors who purchased CHOW securities during this period allegedly suffered substantial losses when the manipulation was revealed.
“Most CHOW shareholders never file or join the class action, which means they miss out on potential recovery funds,” said Attorney Joseph Levi.
Case Name: Hansink v. ChowChow Cloud International Holdings Limited et al.
Case No.: 1:26-cv-2063
Jurisdiction: U.S. District Court, Southern District of New York
Filed on: March 13, 2026
ChowChow Cloud International Holdings Limited is a Cayman Islands holding company with operations in Hong Kong, operating through Sereno Cloud Solutions HK Limited and serving the Asia-Pacific market, including Hong Kong and Singapore that purports to provide one-stop cloud solutions supporting companies across the IT industry value chain, including digital transformation consulting, professional IT services, AI-powered cloud managed services, and IT infrastructure solutions, and is a controlled company, with Rainbow Sun Enterprises Limited holding approximately 69.68% of voting power post-IPO.
September 16, 2025 – December 10, 2025, inclusive.
Investors who purchased or otherwise acquired CHOW securities during the Class Period, including ordinary shares traded on the NYSE American under ticker symbol CHOW, may be eligible to join the ChowChow Cloud International Holdings Limited (CHOW) class action lawsuit.

The complaint targets ChowChow Cloud International Holdings Limited, its Chief Executive Officer and Chairman Yee Kar Wing, Chief Operating Officer Hui Wai Ming, Chief Financial Officer Wong Chung Wai, underwriter US Tiger Securities, Inc., and auditor Assentsure PAC, asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
The company completed its initial public offering (IPO) on September 16, 2025, raising $10.4 million in gross proceeds from 2.6 million ordinary shares priced at $4.00 per share. In its prospectus issued that same day, the company portrayed itself as a pioneer in cloud solutions and highlighted substantial growth, stating that revenue had increased 28.6% from HK$141.4 million in 2023 to HK$181.8 million in 2024.
On May 28, 2025, Assentsure PAC, a Singapore-based, PCAOB-registered auditor had issued an opinion stating that the company's consolidated financial statements presented fairly, in all material respects, the financial positions and results of operations in conformity with generally accepted accounting principles. According to the complaint, these positive statements allegedly omitted critical facts about the true nature of trading activity in CHOW securities, including that CHOW stock traded at artificially inflated prices during the class period. Investors allege the company failed to disclose that its stock was subject to a market manipulation and fraudulent promotion scheme involving social-media based misinformation and impersonators posing as financial professionals. The complaint alleges that CHOW's public statements and risk disclosures omitted any mention of the realized risk of fraudulent trading or market manipulation being used to drive the stock price, leaving securities at unique risk of sustained trading suspension on NYSE American and severe volatility-induced decline.
The complaint further alleges that the sole underwriter on the IPO, Tiger Securities, had been fined and censured by FINRA (the Financial Industry Regulatory Authority) in April 2025 for failing to have a reasonable system in place to identify potentially suspicious deposits of low-priced securities. As a result of these alleged omissions, investors claim that defendants' positive statements about the company's business, operations, and prospects were materially misleading and lacked a reasonable basis, violating Sections 10(b) and 20(a) of the Exchange Act.
The alleged scheme was revealed on December 10, 2025, through catastrophic market action rather than company disclosure. Trading in CHOW ordinary shares was halted twice by NYSE American that day as the stock price collapsed from a closing price of $11.70 per share on December 9, 2025, down to $1.83 per share at closing on December 10, 2025, a single-day decline of 84.3%.
At approximately 11:05 AM EST, a surge of sell orders and volume of about 360,000 shares caused the price to plummet from $11.95 per share to $10.59 per share in mere minutes, triggering the first trading halt, which remained in effect from 11:07 AM to 12:37 PM EST. NYSE American halted trading a second time from 3:44 PM EST until 3:49 PM EST before the stock ultimately closed at $1.83 per share. The following day, December 11, 2025, the company issued a press release acknowledging unusual trading activity in its ordinary shares on December 10 and 11, 2025. Management stated the company had made inquiries and was unable to determine whether corrective actions were appropriate, and that there had been no material development in its business and affairs not previously disclosed or any other reason to account for the unusual market action.
The stock exhibited extreme volatility throughout the class period on the NYSE American exchange. On its first trading day following the IPO on September 16, 2025, CHOW ordinary shares opened at $8.00 per share-double the IPO price of US$4.00 per share-and surged to an intraday high of $21.91 per share before closing at $12.61 per share on volume of 1.4 million shares, a one-day gain of 215.25%. The price then declined over the next three trading sessions, falling 32.6% to $8.50 per share on September 17, another 36.7% to $5.38 per share on September 18, and an additional 6.9% to $5.01 per share on September 19, 2025, representing a cumulative three-day decline of 60.3% from the first-day closing high.
In early December 2025, the stock price surged again on record-breaking trading volume, rising 18.1% to $11.20 per share on December 8 on volume of over nine million shares, then climbing another 4.5% to $11.70 per share on December 9 on volume of over 6.5 million shares, despite the absence of any news relating to or filing by the company. On December 10, 2025, the alleged pump-and-dump scheme collapsed with the 84.3% single-day price decline to $1.83 per share on volume of just under 13.5 million shares, causing catastrophic losses to investors.
● The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.
● The Court will then consider motion for class certification.
● The Court will later consider a Motion to Dismiss.
Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






A securities fraud class action under the Securities Exchange Act, including Sections 10(b) and 20(a) and Rule 10b-5 has been filed against Oddity Tech Ltd. (NASDAQ: ODD) and two of its senior executives on behalf of investors who purchased the company's securities including Class A ordinary shares between February 26, 2025 and February 24, 2026. Investors allege the company misrepresented the strength and sustainability of its digital advertising model while touting consistent revenue growth and strong financial performance. “During this period, an algorithm change by the company’s largest advertising partner was allegedly diverting Oddity’s advertisements to lower quality auctions at abnormally high costs, significantly increasing customer acquisition costs and allegedly undermining the strength, stability, and sustainability of Oddity’s digital operating model. When the truth emerged on February 25, 2026, the stock plummeted nearly 50% in a single day, erasing substantial shareholder value.
Case Name: Travis Peters v. Oddity Tech Ltd.
Case No.: 1:26-cv-02046
Jurisdiction: U.S. District Court, Southern District of New York
Filed on: March 12, 2026
Oddity Tech Ltd., based in Tel Aviv, Israel, is a consumer technology company that builds digital-first brands for the beauty and wellness industries in the U.S. and internationally, and its Class A ordinary shares trade on the NASDAQ under ticker ODD, serving consumers through an artificial intelligence-driven online consumer technology platform using data science, machine learning, and computer vision capabilities across its Il Makiage and SpoiledChild brands.
February 26, 2025 - February 24, 2026, inclusive.
Investors who purchased or otherwise acquired Oddity securities including Class A ordinary shares on the NASDAQ during the Class Period may be eligible to join the Oddity Tech Ltd. (ODD) class action lawsuit.

The lawsuit targets Oddity Tech Ltd., Chief Executive Officer Oran Holtzman, and Global Chief Financial Officer Lindsay Drucker Mann for allegedly making materially false and misleading statements about the company's business operations and financial prospects throughout the class period in violation of the Securities Exchange Act. According to the complaint, executives repeatedly emphasized the power and resilience of Oddity’s direct-to-consumer digital model while the company was allegedly experiencing advertising-related issues tied to algorithm changes at its largest advertising partner, which the complaint says increased customer acquisition costs and negatively impacted business and financial prospects.
On February 25, 2025, Holtzman announced that the company had "once again proved the power of online" and delivered 27% net revenue growth, declaring he remained "bullish on ODDITY's future" and that the company had "positioned ourselves to win in the most important growth areas in our industry." Three months later on April 29, 2025, Holtzman stated that first quarter results "exceeded our expectations across all metrics" and allowed the company to "raise our full year outlook," while CFO Lindsay Drucker Mann announced the company was "pleased" with results that "beat our guidance across revenue, gross margin, adjusted EBITDA, and adjusted EPS." This pattern continued through the year. On August 4, 2025, both executives again announced that "momentum continued" with "yet another beat and raise" and expressed confidence in raising the full year outlook. On November 19, 2025, they repeated similar claims about "strong third quarter results" that "once again exceeded our guidance" and gave them "confidence to once again raise our full year outlook."
Throughout this period, investors allege that an algorithm change by Oddity's largest advertising partner was diverting the company's advertisements to lower quality auctions at abnormally high costs, negatively impacting the business and financial prospects that executives were publicly celebrating by driving higher acquisition costs and impairing digital advertising efficiency. The complaint alleges that defendants overstated the overall strength, stability, and sustainability of Oddity's digital operating model and market position while these fundamental problems were undermining the business and omitted material facts about the effect of the advertising partner's algorithm changes.
The truth allegedly began to emerge on February 25, 2026, when Oddity issued a press release announcing its fourth quarter and full year 2025 results. CEO Holtzman disclosed that the company "experienced a dislocation in our account with our largest advertising partner that we believe was driven by algorithm changes which diverted us to lower quality auctions at abnormally high costs," resulting in "significant increases in new user acquisition costs that are not correlated with the market or our historical experience."
CFO Mann further stated that the company had “observed that something was different in the second half of 2025” and announced that, “given the dislocation we are experiencing in acquisition costs, we expect first quarter 2026 revenue to decline approximately 30% year-over-year.” According to the complaint, these disclosures undermined defendants’ prior statements about the strength and sustainability of Oddity’s digital operating model
These revelations cast doubt on the executives' repeated statements throughout the Class Period about the strength of the company's business model and on the confidence they expressed while repeatedly beating guidance and raising full year outlooks by acknowledging a material impact from advertising algorithm changes. Management stated only that they had "observed that something was different in the second half of 2025," without saying when the issue began.
On February 25, 2026, following the disclosure of the advertising algorithm problems and the 30% expected revenue decline, Oddity's Class A ordinary shares (ticker ODD) on the NASDAQ fell $14.28, or 49.21%, closing at $14.74 per share. The single-day collapse wiped out nearly half the company's market value as investors reacted to the company's disclosure of an advertising dislocation at its largest partner that management said they had observed in the second half of 2025, which the complaint alleges significantly increased customer acquisition costs and undercut the digital model executives had repeatedly praised.
● The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.
● The Court will then consider motion for class certification.
● The Court will later consider a Motion to Dismiss.
Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






A securities fraud class action under the Securities Exchange Act of 1934 has been filed against Trip.com Group Limited (NASDAQ: TCOM) and two executives for alleged misrepresentations during the period from April 30, 2024 to January 13, 2026. Investors allege that the company and its leadership understated the regulatory risks facing Trip.com stemming from monopolistic business practices and antitrust violations. On January 14, 2026, Bloomberg reported that China’s State Administration for Market Regulation had launched an antitrust investigation into Trip.com, accusing the company of abusing its market position and engaging in monopolistic practices. According to the complaint, the news was followed by a two-day decline in Trip.com’s ADS price.
Case Name: De Wilde v. Trip.com Group Limited et al.
Case No.: 1:26-cv-01420
Jurisdiction: U.S. District Court, Eastern District of New York
Filed on: March 11, 2026
Trip.com Group Limited is a leading global one-stop travel service provider that integrates a comprehensive suite of travel products and services as an online travel platform with differentiated travel content. The company serves as the go-to destination for travelers in Asia and increasingly for travelers worldwide, leveraging its one-stop-shop model, high-quality service, and advanced technology across accommodation reservation, transportation ticketing, packaged tours, and corporate travel management to expand its global reach in China and other key markets.
April 30, 2024 - January 13, 2026, inclusive.
Investors who purchased or otherwise acquired publicly traded Trip.com securities during the Class Period and suffered losses may be eligible to join the Trip.com Group Limited (TCOM) class action lawsuit as class members, including purchasers of American Depositary Shares listed on the NASDAQ under the ticker TCOM.

The complaint targets Trip.com Group Limited, Chief Executive Officer Jane Jie Sun, and Chief Financial Officer Cindy Xiaofan Wang for allegedly misleading investors about the regulatory threats facing the company in violation of federal securities laws. According to investors, the defendants recklessly understated the antitrust risks stemming from Trip.com's monopolistic business activities and failed to disclose material regulatory risk during a period when regulatory scrutiny was intensifying.
On April 29, 2024, Sun and Wang signed the company's 2023 Annual Report on Form 20-F, which acknowledged that Trip.com's strategy to invest in complementary businesses and establish strategic alliances "involves significant risks and uncertainties that may have a material adverse effect on our business, reputation, financial condition, and results of operations" but, according to the complaint, those statements were misleading because they allegedly understated the regulatory risk facing Trip.com in light of its alleged monopolistic business activities and China’s anti-monopoly enforcement environment.
Nearly a year later, on April 11, 2025, the executives repeated virtually identical language in the 2024 Annual Report on Form 20-F, again presenting antitrust risks as contingent concerns. The complaint alleges those statements were materially false and misleading because defendants allegedly understated the regulatory risk Trip.com faced as a result of its alleged monopolistic business activities.
Regulatory scrutiny had been building for months, with authorities convening a meeting of five online tourism platforms in August to discuss antitrust concerns and summoning Trip.com in September by the Zhengzhou market regulator for violations of rules against unfair restrictions on merchants. Rather than acknowledge this mounting pressure, investors allege the company continued to frame regulatory risk as hypothetical and concealed the scope of the antitrust investigation risk.
On January 14, 2026, Bloomberg published an article entitled "China Starts Antitrust Probe of Trip.com Ahead of Travel Peak," revealing that China's State Administration for Market Regulation (the national market regulator) had launched a formal investigation into the company as an antitrust probe. The regulator accused Trip.com of abusing its market position and engaging in monopolistic practices, taking aim at what it described as "the country's dominant online travel platform" and citing alleged unfair restrictions.
Trip.com issued a brief statement saying it would cooperate with the investigation initiated by SAMR. According to the complaint, the news contradicted the company’s prior disclosures, which had framed antitrust risk as a potential future concern. Instead, investors learned that Trip.com was already under active investigation for allegedly monopolistic conduct, exposing the gap between what executives had disclosed and the regulatory reality the company faced in China.
According to the complaint, Trip.com’s ADS price fell sharply following the antitrust investigation announcement. On January 14, 2026, the company's American Depositary Shares (NASDAQ: TCOM) plummeted $12.90 per ADS, a decline of 17.05%, closing at $62.78 in heavy trading. The selloff continued the following day as shares fell an additional $1.48 per ADS, or 2.35%, to close at $61.30 on January 15, 2026 marking an approximately 19% stock price decline over two trading sessions.
● The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.
● The Court will then consider motion for class certification.
● The Court will later consider a Motion to Dismiss.
Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






A securities fraud class action has been filed against Camping World Holdings, Inc. (NYSE: CWH) and certain executives for alleged misrepresentations made between April 29, 2025 and February 24, 2026 (the Class Period), alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Investors allege that the company overstated its ability to surgically manage inventory using sophisticated data analytics and tighter SG&A expense management and disclosure controls while claiming to experience strong retail demand and maintaining a healthy balance sheet.
In reality, the complaint alleges, the company required strict corrective inventory management objectives that would negatively impact gross profit and margins, and its inadequate systems and disclosure controls and procedures prevented accurate disclosures about its financial health. When the truth emerged through a series of disclosures in late 2025 and early 2026, including Q3 2025 and Q4 2025 financial results and revised guidance, the company's stock price fell sharply, after trading at artificially inflated prices during the Class Period, causing significant losses to investors.
Case Name: Siverd v. Camping World Holdings, Inc.
Case No.: 1:26-cv-02710
Jurisdiction: U.S. District Court, Northern District of Illinois
Filed on: March 10, 2026
Camping World Holdings, Inc., a publicly-traded RV retail and services company, headquartered in Lincolnshire, Illinois, retails recreational vehicles (RVs) and RV retail and related services in the United States, and its Class A common stock trades on the NYSE under the symbol CWH.
April 29, 2025 – February 24, 2026, inclusive.
All persons and entities that purchased or otherwise acquired Camping World Holdings, Inc. (CWH) securities during the Class Period and were damaged thereby may be eligible to join the action.

The complaint targets Camping World Holdings, Inc. and three executives: Marcus A. Lemonis, who served as Chief Executive Officer from 2006 through December 31, 2025; Matthew D. Wagner, who became CEO on January 1, 2026 after serving as President; and Thomas E. Kirn, the company's Chief Financial Officer. Investors allege these defendants made materially false and misleading statements about the company's inventory management capabilities, retail demand, and balance sheet strength, SG&A expense control, throughout the class period, causing Camping World securities to trade at artificially inflated prices.
On April 29, 2025, President Matthew Wagner issued a press release stating that the business continued to exhibit consistent growth and expressing confidence in delivering growth in excess of low-double digits in used units and low single digits in new units, with vehicle gross margins within historical range and SG&A as a percentage of gross profit improving by 600-700 basis points (guidance communicated to investors). The following day, CEO Marcus Lemonis told investors during the first quarter earnings call that the company had taken decisive action on SG&A and that it had a very healthy balance sheet with cash; used inventory, parts, and real estate owned free and clear; and available revolvers.
On July 29, 2025, Lemonis stated in a press release that the company continued to surgically manage its inventory to find volume and gross profit opportunities leveraging sophisticated data analytics and the strength of its balance sheet to put the right inventory on the ground at the right time and the right price. During the July 30, 2025 earnings call, Lemonis claimed the balance sheet had never been stronger, while President Wagner stated the company had played a much more competitive and intelligent game in terms of inventory management.
According to the complaint, these statements were materially false and misleading because the company had overstated its ability to surgically manage inventory to optimize profit and data analytics claims, overstated the retail demand it was experiencing or reasonably expected, and concealed that it would require strict corrective inventory management objectives that would negatively impact gross profit and margins. The complaint further alleges that the company's inadequate systems and processes prevented it from ensuring reasonably accurate public statements and financial disclosures and guidance about the health of its balance sheet and its ability to manage SG&A expenses with a reasonable basis. The complaint asserts claims under the Securities Exchange Act of 1934, including Sections 10(b) and 20(a), for false statements and material omissions that misled investors.
The truth began to surface on October 28, 2025, when Camping World Holdings, Inc. released its third quarter 2025 financial results after market close, revealing that new vehicle revenue had decreased $58.1 million or 7.0%, the average selling price of new vehicles sold had decreased 8.6%, new vehicle gross margin had decreased 81 basis points, and total gross margin had decreased 27 basis points , a corrective disclosure signaling weaker retail demand than previously represented. Management warned that affordability was still top of mind for consumers and stated the company was deliberately setting conservative new volume growth assumptions.
The next day, during the earnings call on October 29, 2025, CEO Lemonis admitted he had been more aggressive in pushing the team to liquidate inventory and acknowledged that when looking back on what happened over history, the company may have gone into years with a delusion about what was happening because it was outperforming everyone else, only to find out 18 months later that it had to discount its way out of inventory , undermining prior inventory management assertions.
The full extent of the problems became clear on February 24, 2026, when Camping World Holdings, Inc. released its fourth quarter 2025 results after market close, disclosing that it had implemented strict corrective inventory management objectives to structurally improve turnover rates, which were expected to result in gross margin headwinds in the first half of 2026. The company reported a net loss of $109.1 million, an adjusted EBITDA loss of $26.2 million, a gross profit decrease of $38.7 million, and announced it was pausing its quarterly dividend effective immediately. Management also disclosed new vehicle gross margin of 12.3% (a 291 basis-point decrease) and used vehicle gross margin of 16.0% (a 277 basis-point decrease), reflecting the margin impact of accelerated inventory liquidation. SG&A improved by approximately 190 basis points, which was below the previously issued guidance of 300–400 basis points.
During the February 25, 2026 earnings call, CFO Thomas Kirn admitted that the largest driver of the delta in fourth quarter results versus expectations was the December hit to vehicle margins as the company accelerated the cleansing of its inventory, with management estimating this strategy could negatively impact EBITDA by about $35 million in 2026, particularly in the front half of the year, while the company guided 2026 adjusted EBITDA to $275 million to $325 million. These revelations directly contradicted the prior representations about surgical inventory management, sophisticated data analytics, strong balance sheet health, and the company's ability to achieve its guidance and SG&A expense targets.
Following the October 28, 2025 after-market disclosure of third quarter results (a corrective disclosure), Camping World Holdings, Inc.'s stock fell $4.17, or 24.8%, to close at $12.65 per share on October 29, 2025, on unusually heavy trading volume on the NYSE: CWH. Following the company's release of its fourth quarter 2025 results on February 24, 2026 after market close, the stock price fell an additional $1.79, or 16.5%, to close at $9.06 per share on February 25, 2026, again on unusually heavy trading volume , reflecting investor reaction to revised guidance and the dividend suspension and marking consecutive stock price declines tied to corrective disclosures.
● The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.
● The Court will then consider motion for class certification.
● The Court will later consider a Motion to Dismiss.
Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






A federal securities fraud class action alleging violations of the Securities Exchange Act of 1934, including Sections 10(b) and 20(a) and Rule 10b-5, has been filed against Nektar Therapeutics (NASDAQ: NKTR) and three of its executives for alleged misrepresentations made between February 26, 2025 and December 15, 2025.
Investors allege the company misled them about the integrity of its REZOLVE-AA Phase 2b clinical trial for alopecia areata, repeatedly claiming that enrollment followed proper protocol standards and excluded ineligible patients. On December 16, 2025, Nektar disclosed in topline results that the trial failed to reach statistical significance due to the inclusion of four patients who should have been disqualified from participation, contradicting months of assurances about rigorous enrollment criteria. As a result of these alleged misrepresentations and the subsequent stock price decline, investors who purchased Nektar securities (NASDAQ: NKTR) during this period suffered significant losses.
Case Name: Michael Schramke v. Nektar Therapeutics et al.
Case No.: 3:26-cv-01951
Jurisdiction: U.S. District Court, Northern District of California
Filed on: March 6, 2026
Nektar Therapeutics is a San Francisco-based biopharmaceutical company publicly traded on NASDAQ: NKTR, focused on discovering and developing therapies that selectively modulate the immune system by stimulating regulatory T cells to treat autoimmune disorders. The company's lead product candidate is rezpegaldesleukin, a regulatory T cell stimulator, a first-in-class IL-2 pathway agonist, for the treatment of alopecia areata and other conditions.
February 26, 2025 – December 15, 2025, inclusive.
Investors who purchased or otherwise acquired Nektar securities (NASDAQ: NKTR) during the Class Period may be eligible to join the Nektar Therapeutics (NKTR) class action lawsuit.

The complaint targets Nektar Therapeutics and three individual executives: Howard W. Robin, the company's Chief Executive Officer, President, and Director; Sandra Gardiner, Interim Chief Financial Officer; and Jonathan Zalevsky, Chief Research and Development Officer. According to investors, these defendants made repeated false statements and material omissions about the REZOLVE-AA clinical trial, a Phase 2b study testing rezpegaldesleukin as a treatment for severe-to-very-severe alopecia areata.
On February 26, 2025, Nektar issued a press release announcing enrollment completion for the trial, stating that enrollment criteria included a diagnosis of severe-to-very-severe alopecia areata as measured using the SALT score at both screening and randomization, and that patients who experienced an unstable course of alopecia areata over the last six months were excluded from the study. During a conference call on March 12, 2025, CEO Howard Robin emphasized that the trial had "unique operational features" designed to "minimize clinical operational risk." That same day, Chief Research and Development Officer Jonathan Zalevsky told investors that patients "had to present with severe-to-very-severe disease" and maintain that condition "for at least six months in order to be eligible for inclusion." On November 6, 2025, Zalevsky reiterated these enrollment criteria, again stating that patients with unstable alopecia areata over the previous six months were excluded.
Investors allege that throughout this period, enrollment in the REZOLVE-AA trial had not actually followed applicable instructions and protocol standards , including major study eligibility violations. The complaint alleges that this failure was likely to have a significant negative impact on the trial's results , including statistical significance, meaning the trial's overall integrity and prospects were materially overstated in defendants' public statements in violation of federal securities laws.
On December 16, 2025, Nektar issued a press release during pre-market hours announcing topline results from the REZOLVE-AA trial. The trial failed to reach statistical significance, with the primary endpoint , following a 36-week induction period, showing mean percent SALT reduction , a Severity of Alopecia Tool metric, at Week 36 of 28.2% for one treatment arm, 30.3% for another, and 11.2% for placebo. Nektar revealed that four of the 92 patients included in the analysis (the modified intent-to-treat (mITT) population) "were found to have major study eligibility violations that should have disqualified them for randomization into the trial."
During a subsequent call, the Chief Medical Officer explained that two of the four excluded patients had unstable alopecia areata with initial disease diagnosed less than six months prior to randomization, directly contradicting the enrollment criteria defendants had repeatedly emphasized. The officer noted that alopecia areata is considered unstable when diagnosed for less than six months because of the unpredictable nature of its autoimmune response, and that "it's standard practice to exclude these patients from AA studies." Two additional patients were excluded because they initiated treatment before completing the required eight-week washout period for other alopecia areata medications.
These revelations contradicted the company's repeated assurances that enrollment had followed proper protocol standards and excluded ineligible patients.
On December 16, 2025, following the disclosure that the REZOLVE-AA trial failed to reach statistical significance due to enrollment violations, Nektar's stock price (NASDAQ: NKTR) fell $4.14 per share, nearly 8 percent, to close at $49.16 per share.
● The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.
● The Court will then consider motion for class certification.
● The Court will later consider a Motion to Dismiss.
Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure






Introduction to Boston Scientific Corporation (BSX) Securities Class Action Lawsuit
A securities fraud class action has been filed against Boston Scientific Corporation (NYSE: BSX) and several of its executives for alleged violations of federal securities laws between July 23, 2025, and February 3, 2026. Investors allege that defendants made materially false and misleading statements about the company's Electrophysiology business segment (EP), including its Farapulse pulsed field ablation platform, specifically claiming sustained high growth rates, competitive strength, and confidence in future performance while concealing deteriorating market conditions, unsustainable growth trajectories, and intensifying competitive pressures. On February 4, 2026, Boston Scientific Corporation revealed disappointing U.S. EP sales results in an earnings disclosure and issued fiscal 2026 guidance that fell well below expectations, attributing the shortfall to slower market growth and increased competition. The company's stock price plummeted $16.12 per share, a 17.6% decline in a single day, for BSX shareholders, as the truth emerged.
Boston Scientific Corporation (BSX) Securities Lawsuit Case Details
Case Name: John Rudolph Troike v. Boston Scientific Corporation, et al.
Case No.: 4:26-cv-40075
Jurisdiction: U.S. District Court, District of Massachusetts
Filed on: March 5, 2026
Boston Scientific Corporation (BSX) Company Profile
Boston Scientific Corporation is a global company headquartered in Marlborough, Massachusetts that develops, manufactures, and markets medical devices used across various specialties, and is publicly traded on the NYSE (ticker: BSX). The company's Electrophysiology business unit develops and manufactures products used in the detection and treatment of heart rate and rhythm disorders, including cardiac rhythm management, with the Farapulse PFA system as its key product offering, a pulsed field ablation technology within cardiovascular and electrophysiology medicine.
Boston Scientific Corporation (BSX) Securities Lawsuit Class Period
July 23, 2025 – February 3, 2026, inclusive.
Investors who purchased or otherwise acquired Boston Scientific Corporation common stock during the Class Period may be eligible to join the Boston Scientific Corporation (BSX) class action lawsuit.

Allegations in the Boston Scientific Corporation (BSX) Securities Class Action Lawsuit
Investors allege that Boston Scientific Corporation and five of its executives, in this federal securities class action-Chairman and CEO Michael F. Mahoney, CFO Jonathan R. Monson, Chief Medical Officer Kenneth M. Stein, Executive Vice President of Cardiology Joseph M. Fitzgerald, and Global President of Electrophysiology Nicholas Spadea-Anello-made materially false and misleading statements about the company's growth prospects and competitive position for its U.S. Electrophysiology (EP) segment. On July 23, 2025, Mahoney announced in a press release that the quarter delivered "exceptional top-line performance" and positioned the company for "differentiated long-term performance.” During the earnings call, he stated that the company expected "continued high single-digit growth led by our proprietary technologies" in the second half of the year , including the Farapulse PFA platform. On September 30, 2025, at the company's Analyst/Investor Day Conference, Fitzgerald characterized the EP market as "the largest in medtech and the fastest growing in medtech" within cardiovascular medicine, projecting that the EP market would grow at 15% over the long-range plan and that the Company would "outpace the market." On December 2, 2025, at the Citi Annual Global Healthcare Conference, Fitzgerald assured investors that the company had "a very good understanding of what competition we will face and in what time frame" in the U.S. EP market.
According to the complaint, defendants provided these overwhelmingly positive statements while concealing material adverse facts about the true state of Boston Scientific Corporation's U.S. EP segment and the sustainability of EP revenue growth. Management allegedly knew that the segment's growth rate was unsustainable in U.S. procedures and that it was approaching an earlier tipping point than the market was anticipating. The complaint alleges that defendants failed to disclose material adverse trends affecting procedure volumes, competitive pressures, and regulatory and reimbursement headwinds for the EP segment that would ultimately necessitate lowered expectations. Due to defendants' statements of confidence and lofty expectations, analysts were left surprised by Boston Scientific Corporation's net income miss and underwhelming guidance for the first half of fiscal 2026 for investors in BSX common stock.
The Truth Emerges
On February 4, 2026, Boston Scientific Corporation published a press release and accompanying earnings disclosure announcing fourth quarter and full year 2025 results that included a significant disappointment in U.S. EP sales and issued guidance for fiscal 2026 that fell well below expectations reflecting a slower EP market outlook. The company attributed its results and dismal guidance to a combination of slower than expected market growth alongside increased competition in pulsed field ablation. During the earnings call, Mahoney stated that the EP market in the fourth quarter "was closer to 18% to 20% growth rather than what some other companies have claimed at 25%," calling the market for 2026 "about 15% growth." He also acknowledged that "with new entrants coming, it's not surprising that we lost some share" in U.S. electrophysiology.
These revelations directly contradicted management's previous claims of a growing EP business and assertions that they had "a very good understanding of what competition we will face and in what time frame" from prior investor presentations and conferences. The disappointing results and lowered guidance exposed that the growth trajectory and competitive strength defendants had repeatedly touted throughout the class period were not sustainable according to the complaint.
Market Reaction
Investors and analysts reacted immediately to the corrective disclosures following Boston Scientific Corporation's revelation. From a closing market price of $91.62 per share on February 3, 2026, for NYSE: BSX common stock, Boston Scientific Corporation's stock price fell to $75.50 per share on February 4, 2026, a decline of about 17.6% in the span of just a single day, reflecting a significant stock price decline linked to the EP guidance.
Next Steps
● The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.
● The Court will then consider motion for class certification.
● The Court will later consider a Motion to Dismiss.
Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





